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Abstract 
Multiple sclerosis (MS) is a common autoimmune, neurological disease. The cause of MS is 
unknown, however, the leading hypothesis is that it is developed in genetic predisposed 
individuals triggered by environmental factors. The genetics is complex, where it is thought 
that several susceptibility genes each exert a small effect. One of the genes that have been 
identified to be associated with MS is the CLEC16A gene, which contains several MS-
associated single nucleotide polymorphisms. Gaining an understanding of the functions of the 
MS susceptibility genes can contribute to insights in the underlying mechanisms leading to 
MS development. 
 
Earlier studies about the protein, C-type lectin like domain family 16A encoded by the 
CLEC16A gene, has shown that it plays a role in autophagy and endosomal maturation. Its 
role in immune cells is not determined. The subcellular localization of the protein seems to be 
different in different cell types and has not been studied in T cells before.  
 
The aim of my project was to investigate the subcellular localization of CLEC16A in T cells 
and its role for endosomal distribution in T cells using confocal microscopy. Jurkat T cells 
were transfected with CLEC16A fused with a tag. To ensure that the tag did not influence the 
localization, both C-terminal and N-terminal tagged CLEC16A constructs were created. 
Confocal microscopy analyses showed that CLEC16A was partially co-localized with Rab4a, 
which is localized in rapid recycling-endosomes. To examine the role of CLEC16A in 
endosomal distribution, we analysed endosomal markers by confocal microscopy in Jurkat T 
cells transfected with CLEC16A small interfering RNA (siRNA) or a CLEC16A expression 
plasmid and compared with corresponding controls. The endosomes investigated were; Rab5-
positive (early endosome), Rab4a-positive (rapid recycling endosome) and LAMP1-positive 
(lysosomal protein).  
 
Our data indicate that CLEC16A knockdown causes an accumulation of Rab5-positive 
endosomes, a similar phenotype has been observed in Rab4-mutant cells. These findings 
indicate a possible function for CLEC16A in rapid recycling-dependent processes in T cells.  
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1 Introduction	  
This thesis explores the role of a protein, encoded by a multiple sclerosis (MS)-associated 
gene, in T cells6. The introduction first gives a short description of the immune system and 
potential important processes for the protein studied, before a section describing MS and MS 
genetics. Finally, the introduction is more specific to the protein studied. In the whole thesis, 
T cells are in focus.  
 
1.1 The	  Immune	  system	  	  
The immune system is the body‘s defence against foreign invaders and protects against 
diseases. A complex system of cells and molecules interact to extinguish the invaders. The 
innate immune system is the first line of defence after a pathogen has got past the physical 
barriers. It can discriminate between host cells and pathogens by recognition of patterns on 
the surface of the pathogen, and initiate an unspecific immune response as well as activating 
the adaptive immune response. The adaptive immune system is highly specific and acts as a 
second line of defence if the pathogens are able to get past the innate immune system. The 
adaptive immune system is characterized by specific recognition, mediated through cell-
surface receptors on specific immune cells, B and T cells. 
  
1.1.1 T	  cell	  activation	  
The major players in the adaptive immune system are T and B cells. T cells are divided in 
two types; helper T cells (CD4+), which is stimulating and activating other cells in both the 
innate and the adaptive immune system, and cytotoxic T cells (CD8+), which kills infected 
cells. CD4+ T cells are further divided in groups depending on their function and their 
cytokine production.  
 
T cells are activated through interactions with the T cell receptor (TCR), if it is recognizing 
its specific antigen. The TCR forms a complex on the cell surface, composed of the TCR, 
CD3 and the ζ chain. For the activation to take place, the naïve T cell requires two signals 
(figure 1.1) (1). Binding between a professional antigen-presenting cell´s (APC) major 
histocompatibility complex (MHC)-peptide complex and a naïve T cell´s TCR with a co-
receptor (CD4 or CD8) generates the first signal. The second signal is generated from the 
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binding of co-stimulatory receptor B7, which is induced by pathogens and only expressed on 
professional APCs, to its ligand CD28 on the Naïve T cell (2).  
 
 
Figure 1.1. The T cell receptor (TCR) complex during T cell activation (here illustrated for a 
CD4+ T cell). The TCR interacts with a major histocompatibility complex (MHC) molecule with a 
specific antigen bound. The complex is expressed on the cell surface at antigen-presenting cells 
(APC). In addition the co-receptor (CD4 or CD8) interacts with the MHC molecule (class II for CD4 
and class I for CD8). This interaction give one signal to the cell, but to become activated the T cell 
needs and additionally signal from interactions between CD28 on the T cell and B7 on the APC.   
 
Upon T cell activation, CD3 and ζ chain are responsible for signalling further into the interior 
of the cell. CD3 has a tail on the cytosolic side of the membrane, containing immunoreceptor 
tyrosine-based activation motifs (ITAMs). ITAMs associate with tyrosine kinases that 
become activated upon receptor clustering, and phosphorylate the ITAM motifs. The 
phosphorylated tyrosines serve as docking- and activation sites for enzymes and other 
signalling-molecules, which can start an intracellular signalling cascade, resulting in 
alterations in gene expression (3). 
 
Endsomal	  pathway	  
There are many cellular processes that use the endosomal pathway, including immunological 
processes, for instance antigen presentation by APCs, T cell activation and signalling (4).  
For cellular functions, endosomal pathways are of special importance during endocytosis, 
when extracellular material is internalized through invaginations of the plasma membrane. 
The transport into the interior of the cell proceeds through membrane enclosed vesicles called 
endosomes. GTPases and its effectors are some of the proteins that define the membranes of 
the endosomes e.g. the GTPase Rab5, which is localized at early endosomes, Rab4 at rapid 
recycling endosomes, Rab7 at late endosomes and Rab11 at slow recycling endosomes 
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(figure 1.2). Endocytosed material, like a receptor and its cargo, is first transported to early 
endosomes, where the cargo is sorted. From early endosomes, the cargo and receptor can be 
sent to degradation in lysosomes or the receptor can be rapidly recycled back to the plasma 
membrane in Rab4-positive endosomes. The receptors can also be sorted to Rab11-positive 
endosomes and be recycled back to the membrane through slow recycling (figure 1.2) (5-7). 
These mechanisms can regulate a signalling process by sending receptors to lysosomes for 
degradation to decrease a signal, or by recycle the receptors to the plasma membrane to 




Figure 1.2. A simplified overview of Rab4-, Rab5-, Rab7- and Rab-11 endosomes and their 
transport routes for cargo from the plasma membrane. Rab5 (green) is located in early 
endosomes, Rab4 (orange) in rapid recycling endosomes, Rab7 (blue) in late endosomes and Rab11 
(violet) in slow recycling endosomes. (1) Internalized material from endocytosis are transported from 
the plasma membrane and routed into early endosomes (Rab5), where they e.g. can be (2) recycled 
back to the plasma membrane by Rab4-recyclings endosomes, (3) be sent to late endosomes, which 
will fuse with lysosome and degrade the content or (4) they can be sent to Rab11-recycling 
endosomes which recycle the cargo back to the plasma membrane in a slow route. 
 
Endocytic vesicles leaving early endosomes after sorting, mature into late endosomes by 
acidifying the environment (lowering the pH) (9). Late endosomes mature into lysosomes by 
further acidification or by fusing with existing lysosomes (10).  
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Recycling	  endosomes	  
For Rab4 GTPases there are two known isoforms (called Rab4a and Rab4b), both are 
localized in the same compartment and seem to have the same function; recycling receptors 
back from early endosome to the plasma membrane through rapid recycling (11). They have 
been indicated to be involved in MHC class II antigen presenting on B cells, since the 
presentation is blocked in Rab4-mutant cells (12). In addition they have been indicated to 
recycle tyrosine kinases, integrins (13), TCRs (during T cell activation) among others (14). 
Rab11 is responsible for the slow recycling pathway between recycling endosomes and 
plasma membrane. Cellular functions where Rab11 have been implicated are autophagy and 
cytokinesis among others (13).   
 
Endosomal	  role	  in	  T	  cell	  activation	  
Interactions between MHC and TCR during T cell activation form an immunological synapse 
when clustering together with co-receptors and co-stimulatory signals (figure 1.3) (15). When 
T cell activation is initiated, the Golgi apparatus and recycling-endosomes are polarized close 
to the immunological synapse (16). TCRs are recycled to the immunological synapse on the 
plasma membrane, using both rapid recycling (Rab4-positive) and slow recycling (Rab11-
positive) (14, 17, 18). The TCR recycling during T cell activation has been demonstrated to 
enhance the amount of TCR molecules delivered to the immunological synapse (16). In 
addition, the endosomal pathway has been shown to be important in signalling, since 
signalling complexes are built by delivery from endosomal compartment rather than 
movement in the plasma membrane (19). The endosomal pathway is recycling TCRs even in 
resting T cells (before activation), the constitutively recycled TCRs are a process that 
regulates the T cells ability to be activated (20). 
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Figure 1.3. A simplified overview of the endosomal pathways involved during T cells activation. 
When a T cell is activated, the contact between the T cell receptor (TCR) and major 
histocompatibility complex (MHC) is creating an immunological synapse. The cells polarize 
recycling endosomes and Golgi (not seen) in the direction of the immunological synapse to rapidly 
transport more TCRs and other components to this area. (1) TCRs expressed on the cell surface are 
(2) sorted into Rab5-positive early endosomes. From there, TCR can be (3) rapidly recycled to the cell 
surface where the immunological synapse is being formed, by Rab4 positive endosomes. Or it can be 
transported to the polarized (4) recycling endosomes and be slowly recycled to the immunological 
synapse by Rab11-endosomes.  
 
Endosomal	  pathways	  in	  MHC	  class	  II	  antigen	  presentation	  
MHC molecules are presenting antigens to the T cells. MHC class I molecules present 
antigens for CD8+ T cells and MHC class II molecules present antigens for CD4+ T cells. 
The MHC molecules differ in the antigen source and antigen processing. In addition they 
differ in cell type presenting them. MHC class I is expressed on nearly all cells, meanwhile 
MHC class II is only expressed on professional APCs.  
 
The MHC class II is using the endosomal pathways for the antigen processing and loading. 
The antigens presented by MHC class II originate from extracellular environment by uptake 
through endocytosis. MHC class II transactivator (CIITA) is regulating gene expression of 
MHC class II molecules. When promoting expression, the two transmembrane chains (α and 
β), building the MHC class II molecule, are assembled in endoplasmic reticulum (ER), where 
they also associate with the invariant chain (figure 1.4). The invariant chain is protecting the 
binding cleft of the MHC class II and prevents binding of peptides until reaching the right 
compartment. The complex is transported to MHC class II compartment (MIIC), a late 
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endosome. In MIIC the invariant chain is cleaved, but the part binding to the MHC cleft 
(named Class II-associated invariant chain peptide (CLIP)) is left still binding. The 
internalized proteins are hydrolysed in the endosomal system and in MIIC the hydrolysed 
peptides meet the MHC class II molecules. CLIP is exchanged with a peptide with specificity 
for the binding cleft. The loaded MHC molecule is transported from MIIC to the plasma 
membrane for the presentation of antigens to CD4+ T cells (reviewed in (21)). Upon arrival 
at the plasma membrane it is possible for the complex to be rapidly recycled through the 
early endosome, where antigen exchange can be performed, or they can be sorted for 
degradation in lysosomes (22) (figure 1.4).  
 
Figure 1.4. Overview of MHC class II presentation. (1) CIITA is promoting expression of MHC 
class II. (2) MHC class II chains are associated in ER, where invariant chain is binding to the binding 
cleft of the complex. (3) The complex is transported to Golgi, and from trans golgi network (TGN) 
the complex is sorted to MHC class II compartment (MIIC), and in some cases with a detour to the 
plasma membrane and early endosomes. In MIIC the invariant chain on MHC class II is trimmed to 
CLIP, only binding in binding cleft. (4) Extracellular proteins are endocytosed and hydrolysed in 
endosomal pathway. (5) The hydrolysed peptides are transported to MIIC where they compete on 
being exchanged with CLIP on MHC class II binding cleft. (6) The antigen loaded MHC class II 
complexes are transported to the plasma membrane from MIIC. From the plasma membrane the MHC 
class II can be recycled back and forth. 
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1.1.2 Autophagy	  
Autophagy is a process where the cytosolic content (proteins or entire organelles) is being 
degraded. It is a vital process happening constantly to obtain homeostasis in the cells (23). 
This process is critical for the cells during starvation, growth, activation and proliferation. 
Autophagy has also been implicated in many diseases such as; neurodegenerative diseases 
(24, 25) and autoimmune diseases, like Crohn´s disease (26, 27) and diabetes (28). 
  
Autophagy pass through four phases; nucleation, elongation, fusion and degradation. In 
nucleation, a double membrane (phagophore) is formed and in elongation the membrane is 
engulfing a part of cytosolic content or an organelle. When the membrane closes around the 
cargo it forms an autophagosome. The cargo is degraded when the autophagosome is fused 
with a lysosome (reviewed in (29)). 
 
Autophagy has been implicated to have a role in several immunological processes. For the 
innate immune system, autophagy can be induced by several pattern recognition receptors, 
where autophagy is facilitating several processes including phagocytosis and cytokine 
production (30-33). Autophagy is implicated to have a role for T cell development and T cell 
selection (34). In addition it is suggested to be required for cell-survival for B cell 
development (35).  
 
Autophagy	  in	  T	  cell	  activation	  and	  signalling	  
T cells are known for having a high rate of continuous autophagy and for expressing genes 
linked to autophagy (34, 36, 37). In human CD4+ and CD8+ T cells, the level of autophagy is 
kept constantly low until TCR stimulation, where the level of autophagy have been shown to 
increase (38, 39). In addition, autophagy levels are high in cortical thymic epithelial cells, 
indicating autophagy to be important for T cell development and T cell selection (23, 40).  T 
cells seem to develop normally in thymic tissue in studies using mouse models where 
autophagy is being blocked (34, 41-43). However, for mature T cells, autophagy-deficiency 
has a larger effect, it is giving rise to a reduction in the number of T cells and an increased 
level of apoptosis. In addition, the T cells do not proliferate efficiently after T cell activation 
in cells where autophagy is blocked (34, 43). All the effects mentioned originate probably 
from the cells inability to regulate organelle turnover. The quality control of organelles is 
lacking. In T cells lacking the autophagy machinery, there are an increased number of 
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mitochondria, which are giving high amounts of reactive oxygen species, resulting in 
increased cell death (37, 41). In addition, inability to regulate ER turnover in autophagy 
would result in failure in calcium influx upon T cell stimulation (37).  
 
1.2 Multiple	  Sclerosis	  (MS)	  
A critical task for the immune system is to discriminate self-derived components from non-
self derived components. If the immune response in an organism is turned against its own 
cells or tissue, autoimmunity develops.  
 
Multiple Sclerosis (MS) is characterized as an autoimmune, neurological disease, where an 
inflammation in the central nervous system (CNS) results in demyelination of the myelin 
sheaths. Myelin sheaths insulates nerve fibers and demyelination is causing impaired 
conducting of the impulses in these nerve fibers (44). The prevalence of MS in Norway is 
203 per 100 000 inhabitants, which is among the highest reported worldwide (45). The 
disease typically appears in young adults and females are affected more than twice as often as 
males (46).  
 
1.2.1 Immunopathogenesis	  of	  MS	  
The trigger of MS is not known. CD4+ T cells have for a long time been thought to be the 
major player in MS pathogenesis, a hypothesis that originated from animal models where an 
MS-like disease (experimental autoimmune encephalomyelitis (EAE)) is induced by myelin-
reactive T cells (47-50). The activation of the T cells is thought to occur in lymphoid tissue 
before crossing the blood brain barrier (51, 52). However, both CD4+ and CD8+ T cells have 
been found in MS lesions, where CD4+ T cells predominate in acute lesions and CD8+ T 
cells are more frequently present in chronic lesions (reviewed in(3)). 
 
1.2.2 MS	  genetics	  	  
The cause of MS is unknown. However, both environmental factors, such as smoking, low 
levels of vitamin D and Epstein Barr virus (53), and genetic factors have shown to be 
associated with the disease. The hypothesis is that environmental factors together with 
multiple genes, where each factor exert a relatively small effect, play a role in disease 
development (review (54)). A better understanding of the cause of MS can be achieved by 
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characterizing the role of the MS associated genes and the function of the proteins they 
encode. 
 
The human leukocyte antigen (HLA) gene region was the first gene region that was shown to 
be associated with MS (55). It is the HLA-DRB1*15:01 allele that is exerting the biggest 
known genetic risk for MS (odds ratio =3.1) (56). The first genome-wide association study ( 
GWAS) performed, did confirm the HLA-gene region on chromosome 6, for MS 
susceptibility. In addition, it identified the first non-HLA genes to be associated with MS 
susceptibility (57). The newest GWAS identified 57 MS susceptibility loci, where 29 of these 
loci were novel (56). The majority of the identified genes are involved in immunological 
processes (58). In 2013, another 48 MS susceptibility genes were identified using the 
ImmunoChip genotyping array (59). 
 
Already in the first GWAS from 2007, one of the identified single nucleotide polymorphisms 
(SNP) with a suggestive association with MS was located in the C-type lectin-like domain 
family 16A (CLEC16A) gene (57). Studies (GWAS and ImmunoChip genotyping array) 
performed afterwards have replicated that CLEC16A is a susceptibility gene for MS 
(reviewed in (60)). 
 
16p13	  chromosomal	  region	  and	  the	  CLEC16A	  gene	  
CLEC16A is located at the chromosome region 16p13 in a gene-complex including the 
following genes: MHC class II transactivator (CIITA), dexamethasone-induced (DEXI), 
CLEC16A and Suppressor of cytokine signalling 1 (SOCS1) (figure 1.5 A) (reviewed in (60)). 
Of these genes both CIITA and SOCS1 are identified to be immune regulatory genes (61, 62). 
The protein expressed by CIITA is a master regulator of MHC class II expression (61). As 
described above (in section 1.1.2), MHC class II is only expressed in professional APCs. 
However, studies have shown that some other cells can be induced (by interferon gamma 
(IFNγ) or other stimuli) to express the MHC class II molecules (63-66). The SOCS1 protein 
is encoded from another immune-regulatory gene, which suppresses cytokine signalling (62). 
The function of the protein encoded by the DEXI gene is unknown. Since, several SNPs in 
this region are associated with autoimmunity and CLEC16A (and DEXI) are located in a gene 
region where several other immune regulatory genes are located, the functions of these 
proteins are of interest to identify. 
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The CLEC16A gene contains 238 kb and is composed of 24 exons1. In addition to MS, the 
CLEC16A gene has been shown to be associated with several other autoimmune diseases, 
including, type I diabetes, and Addison´s disease among others (reviewed in (60)), see also 
figure 1.5 B.  
 
       
Figure 1.5. Overview of the CIITA-DEXI-CLEC16A-SOCS1 gene complex and autoimmune 
associated SNPs on the CLEC16A gene. A) The CIITA-DEXI-CLEC16A-SOCS1 gene complex with 
chromosomal location 16p13. B) The CLEC16A gene has several SNPs associated with autoimmune 
diseases, e.g multiple sclerosis (MS), type I diabetes (TID), crohn´s disease (CD), primary adrenal 
insuffienciey (Addisons disease, PAI), primary biliary cirrhosis (PBC), rheumatoid arthritis (RA), 
juvenile idiopathic arthritis (JIA) and alopecia areata (AA). The figure is adapted from (60).  
 
 
1.3 C-­‐type	  lectin	  like	  domain,	  family	  16A	  protein-­‐CLEC16A	  
The full-length CLEC16A gene encodes a protein of 1053 amino acids. Three different splice 
variants of the CLEC16A is known so far, where two are long (24 exons, Q2KHT3-1 and 21 
exons, Q2KHT3-2; figure 1.7 A) and one is short (4 exons, Q2KHT3-3; figure 1.7 A).  
 
  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 (http://genome-euro.ucsc.edu/cgi-bin/hgTracks?db=hg19&position=chr16%3A11038345-
11276046&hgsid=200280572_IZYpmXFAuV4iILaECojM9K4T4W5w). 
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1.3.1 CLEC16A	  expression	  in	  immune	  cells	  
CLEC16A is expressed in different immune cells. The highest expression levels are found in 
monocytes (CD14hi, CD16+ cells), however it is also expressed in CD19+ B cells, CD4+ and 
CD8+ T cells and CD56+ NK cells (Figure 1.6 A). When analysing CD4+ T cells, no 
difference in CLEC16A expression was observed between MS cases and controls. However, 
when sorting the samples for genotype, an increase of CLEC16A expression was found in 





Figure 1.6. MS-risk genotype is correlated with increased CLEC16A expression. Relative 
expression of CLEC16A is normalized to A) RNaseP for primary immune cells (N=3) and B and C) 
TATA-box binding protein (TPB) for CD4+ T cells isolated from 28 MS patients (MS) and 26 
healthy controls (HC). In C the samples are sorted for the CLEC16A SNP, rs12708716 (risk allele=A) 
(Leikfoss, Keshari, Berge, unpublished data).  
 
1.3.2 Structural	  domains	  of	  the	  CLEC16A	  protein	  
As the name CLEC16A suggests, it contains a C-type lectin-like domain (CTLD). CTLD is 
involved in recognition of carbohydrates on the cell-surface (67). However, the CTLD 
domain of CLEC16A is only 23 amino acids long (reviewed in(60)), and it is unlikely that it 
will fold to the proper CTLD domain, which is normally composed of approximately 150 
amino acids (67). CLEC16A also contains a potential ITAM motif, an FPL domain, which is 
a conserved uncharacterized domain, and it is predicted to contain a transmembrane (TM) 
region (figure 1.7 A). In addition, bioinformatic analyses performed by Torbjørn Rognes at 
the Bioinformatics Core Facility at the University of Oslo, indicates an un-ordered structure 
in the C-terminus. The predicted TM and ITAM motifs share some conserved amino acids 
between Homo sapiens, Rattus norwegius and Drosophila melanogaster (figure 1.7 B) 
indicating that the regions are important for the protein. However, the CTLD is conserved 
between Homo sapiens and Rattus norwegius but not further to Drosophila melanogaster.  
 
	   12	  
 
Figure 1.7. Overview of the CLEC16A isoforms with predicted domains and sequence homology 
of the protein sequence of CLEC16A. A) The predicted domains; FPL, trans membrane (TM), 
immunoreceptor tyrosine-based activation motif ( ITAM) and C-type lectin-like domain (CTLD) 
shown in the different splice variants encoded by the CLEC16A gene. In addition, the predicted un-
ordered structure is shown. B) Shows homology between the CLEC16A amino acid sequences 
between Homo sapiens, Rattus norwegius and Drosophila melanogaster. Figure adapted from (60). 
 
1.3.3 The	  subcellular	  localization	  of	  CLEC16A	  
The few studies existing about the function of the CLEC16A protein show different 
subcellular locations of CLEC16A in different cell-types (68, 69). The same applies for Ema, 
CLEC16A´s orthologue in Drosophila melanogaster (70, 71). However, both CLEC16A and 
Ema are detected in the membrane fraction, when a subcellular fractionation is performed 
(68, 71). A report has shown that Ema is an integral membrane protein. In cellular 
fractionation of garland cells from Drosophila Melanogaster, Ema is obtained in the 
membrane fraction, and not extracted by high salt concentrations (71). In another report, 
human CLEC16A was shown to be a membrane-associated protein. In cellular fractionation 
of overexpressed CLEC16A in pancreatic β cells (cell-line Min6 β), CLEC16A is present 
both in cytosolic and membrane fractions. When treated with alkaline carbonate, which 
disrupt protein-protein interactions, meanwhile keeping lipid-protein interactions, the 
localization of the protein is changed to only be in cytosolic fraction. This indicates that 
CLEC16A is associated with the membrane through protein interactions rather than lipid 
interactions (68). 
 
Expression of Ema-green fluorescent protein (GFP) (fused to the N terminal of Ema) in 
garland cells from Drosophila melanogaster has shown that Ema is localized in late 
endosomes (71). Meanwhile, the same Ema-GFP has been shown to localize in the Golgi 
apparatus in fat body cells, salivary gland cells, muscle cells and epithelial cells, all from 
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Drosophila Melanogaster (70). Expression analyses of CLEC16A-TurboGFP (tGFP, fused to 
the N-terminal of human CLEC16A) in a human erythroleukemia cell-line (K562 cells) 
showed that CLEC16A (isoform 1) is localized in rough ER. In the same study, the result was 
not reproducible when using a C-terminally tGFP-tagged CLEC16A, this fusion protein did 
not co-localize with any of the markers they tested (69). Another study using Min6 β cells 
shows that CLEC16A (isoform 2) with a FLAG-tag is localized in the lysosomal-associated 
membrane protein 1 (LAMP1)-positive lysosomal compartment (68). The different 
subcellular localizations for CLEC16A can be in due to different localization in different cell-
types but it can also be that different CLEC16A isoforms localize to different compartments.  
 
1.4 The	  function	  of	  CLEC16A	  
Studies about the function of the proteins, CLEC16A and Ema, have shown that they are 
involved in endosomal trafficking and maturation as well as autophagy (68, 70, 71). In this 
section the potential involvement of CLEC16A in endosomal trafficking, autophagy and T 
cell activation is described.  
 
1.4.1 CLEC16A	  in	  endosomal	  trafficking	  and	  maturation	  
Ema has shown to be involved in endosomal maturation and endosomal trafficking in 
Drosophila melanogaster. In Ema mutant cells, accumulation of large endosomal 
intermediates occur, membrane trafficking is disrupted and failure of proper lysosomal 
degradation is observed. The latter is due to lack of conversion from late endosomes to 
lysosomes. Interestingly, when expressing human CLEC16A in Ema mutant cells, the 
endosomal phenotypes were rescued. This indicates a similar function for the human 
counterpart of Ema (71). In a study using transient transfection of CLEC16A-siRNA in Min 
β cells, late Rab7-positive endosomes were accumulated, indicating that late endosomes are 
not converted into lysosomes (68).  
 
1.4.2 CLEC16A	  in	  autophagy	  
In both Ema mutant fat body cells (from Drosophila Melanogaster) and CLEC16A loss-of-
function fibroblasts, there are defects in autophagy (68, 70). In Ema mutant fat body cells, 
smaller autophagosomes are formed in the early steps of autophagy. Ema seems to be 
required for recruitment of Golgi elements to the autophagosomes, resulting in smaller size of 
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the autophagosomes in absence of Ema (70). Human CLEC16A has been implicated in 
autophagy of mitochondria, a process called mitophagy. Studies in fibroblasts with 
CLEC16A-loss-of-function showed increased mitophagy with impaired fusion between 
autophagosomes and lysosomes, resulting in accumulated autophagosomes containing 
damaged mitochondria (68).  	  
1.4.3 CLEC16A	  in	  T	  cell	  activation	  
The role of CLEC16A in T cell activation has been investigated for B cells (Lymphoblastoid 
cell line, LCL) where CLEC16A was knocked down. Here, they show that there are no 
differences in the B cell activation markers; CD80, CD86, CD40 and HLA-DR for CLEC16A 
knocked down cells compared to controls, indicating that CLEC16A does not influence the 
ability of the B cells to activate T cells. In addition, the study confirmed this by finding that 
there were no differences in T cell proliferation when CD4+ T cells are co-culture with the 
CLEC16A knocked down B cells (69). In contrast, when CLEC16A was knocked down in 
monocyte derived dendritic cells there has been detected a decrease of HLA-II on the cell 
surface, compared to controls. These results indicate that CLEC16A is involved in the 
expression of HLA-II on the cells surface of APCs. If the effect also influence the T cell 
activation has not yet been tested (Marvin Luijn, personal communication). In an unpublished 
study from our lab, the effect of CLEC16A expression for the cell surface expression of 
activation markers (CD25 and CD69) and cytokine secretion (interleukin 2) have been 
measured after T cell activation. Preliminary results indicate that CLEC16A does not 
influence the T cell`s ability to be activated. However, phorbol 12-myristate 13-acetate 
(PMA) and ionomycin were used to induce the activation, and the involvement of CLEC16A 
via activation through the TCR has not been evaluated (unpublished, Leikfoss et al).  	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1.5 Aims	  of	  study	  
The cause of MS is unknown, but it is thought to involve complex interactions between 
several genes together with environmental factors, where each factor exerts a small effect. 
There have been several genome-wide association studies that have identified MS 
susceptibility genes. One of the identified genes is CLEC16A, which contains several MS-
associated SNPs. To understand the cellular mechanisms underlying the disease 
development, the proteins encoded by the MS susceptibility genes should be mapped.  
 
There have been some studies about the function of CLEC16A and Ema (ortholougue in 
Drosophila melanogaster) earlier, which have shown that the protein is involved in 
endosomal trafficking and autophagy. Subcellular localization studies have shown that 
CLEC16A is located in rough ER (erythroleukemia cell-line) and in lysosomes (pancreatic β 
cells). Studies of Ema have shown that it is localized in early endosome and Golgi (in two 
different cell types). The subcellular localization of CLEC16A seems to differ between cell-
types. The function and subcellular localization has not been studied in T cells before.   
 
The aims for this thesis are: 
• To evaluate the subcellular localization of CLEC16A in T cells.  
• Study the role of CLEC16A in endosomal distribution in T cells.  
 
The main approach to reach the aims in this thesis is confocal microscopy. These analyses 
have been complemented by cellular fractionation assays. 
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2 Methods	  
The main goals for this thesis were to investigate the subcellular localization of CLEC16A 
and to examine the possible role of CLEC16A in endosomal distribution. The methods 
performed to reach the goals are described in this section. All materials, equipment, recipes 
and primer sequences are listed in appendix.  
 
2.1 Sub-­‐cloning	  
Sub-cloning was performed to generate plasmids with recombinant deoxyribonucleic acid 
(DNA) encoding N- and C-terminally GFP-tagged CLEC16A. In addition, by removing 
CLEC16A-MYC-DDK from pCMV6-CLEC16A-MYC-DDK an empty plasmid was created 
(generation of all plasmids, are described in section 3.1). The created plasmids were 
transformed into bacteria to be amplified. To express the encoded protein in mammalian 
cells, the plasmids were purified from bacteria and transfected into mammalian cells. A 
flowchart describing the order of the sub-cloning procedure can be seen in figure 2.1.  
 
In this thesis, the Escherichia coli (E.Coli) XL1.Blue bacterial strain was used in all bacterial 
work. The solutions (prior to addition of antibiotics) (recipe is found in appendix 3) and 
equipment used in this work were autoclaved at 121°C for 20 minutes prior to use.  
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Figure 2.1. Overview over the order and steps followed in the sub-cloning. The steps were 
followed in indicated order to generate the plasmids with DNA-constructs described above, and to 
enable them for transfections into mammalian cells. RE= restriction enzyme digestion, O/N =over 
night. Vector is the destination plasmid and insert is the DNA-fragment to be inserted into to the 
vector. All insert- and vector fragments were not Klenow treated.  
 
2.1.1 DNA	  plasmids	  
DNA plasmids are circular DNA-molecules. Plasmids are separated from chromosomal DNA 
in the cell and are replicated independently. They are common in bacteria and can be used as 
molecular tools, like vector for recombinant DNA. Sub-cloning is a technique used to move a 
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This section describes the cloning vectors used in the process of sub-cloning and these are 
also listed in materials (in appendix 2). All vectors in this thesis contain the specific elements 
that are required for the vector to be replicated and amplified when transformed into bacteria. 
They are also so-called expression vectors as they contain elements required for the inserted 
gene of interest to be expressed when transfected into mammalian cells. 
 
pEGFP-­‐N3	  
pEGFP-N3 (Clontech) contains the gene encoding GFP located downstream the multiple 
cloning sites (MCS). The location of the GFP gene makes it suitable for cloning a gene-
fragment in fusion with GFP. The cloned gene-fragment then encodes a protein with GFP 
fused on the C-terminal side of the protein of interest.  
 
In this thesis, the vector was used for generation of C-terminally GFP tagged CLEC16A. It 
was also used as a marker of transfection efficiency measured by flow cytometry (described 
in section 2.2.4). 
 
pCMV6-­‐CLEC16A-­‐MYC-­‐DDK	  
pCMV6-CLEC16A-MYC-DDK (Origene) is a pCMV6-entry vector containing 
complementary DNA (cDNA) of CLEC16A-isoform 1 fused with a MYC-DDK encoding tag 
on the C-terminal side of CLEC16A.  
  
In this thesis, the vector was used to generate both C- and N-terminal GFP tagged CLEC16A. 
It was also used in functional assay to study the subcellular localization of CLEC16A and in 
endosomal distribution studies.  
 
pEGFP-­‐C1-­‐SUMO	  
pEGFP-C1-SUMO was kindly provided by Odd Gabrielsen´s group and is a vector with 
pEGFP-C1 as backbone with a Small Ubiquitin-like Modifier 1 (SUMO1) insert (described 
in (72)). pEGFP-C1 is a vector suitable to fuse cDNA of the gene of interest with GFP, 
generating an N-terminal GFP tagged version of the protein encoded by the gene of interest. 
 
In this thesis, cDNA of SUMO1 was replaced with cDNA of CLEC16A, generating an N-
terminal GFP tag on CLEC16A.   
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2.1.2 Polymerase	  chain	  reaction	  -­‐	  PCR	  
Polymerase chain reaction (PCR) is a technique for amplifying a specific part of a DNA 
sequence. The components needed to run a PCR are; two different gene specific primers (one 
forward primer and one reverse primer), a mix with the four types of nucleotides, a heat 
insensitive DNA polymerase and a suitable buffer. The forward primer together with the 
reverse primer defines the part of the DNA sequence to be amplified. The primers anneal to 
complementary DNA sequences whereas the DNA polymerase binds to the primers and 
incorporate the nucleotides given by the parent DNA strand. One cycle of PCR can be 
divided into three stages. The different stages are defined by specific temperature and 
duration. The stages in PCR are;  
 
1. Denaturation, where the DNA strands separate from each other.  
2. Annealing, the primers anneal to complementary sequences on each strand. Low 
annealing-temperature might give unspecific binding, and high annealing temperature 
may give rise to no binding. Recommended annealing temperature is 5-10°C below 
the melting temperature of the primer. The melting temperature of a primer depends 
on the sequence and also the length of the primer.  
3. Elongation, both strands are being elongated by DNA polymerase.  
 
The cycle is repeated for about 20-30 times.  
 
Procedure:  
Primers (final concentration 0,4 µM), deoxynucleotide (dNTP) (final concentration 0,4 µM), 
10x Pfu DNA Polymerase reaction buffer (final concentration 1x) and template (10 ng) were 
mixed. Autoclaved Milli-Q (MQ)-water was added to a final reaction volume of 20 µl. 
Finally, Pfu Turbo DNA Polymerase (2.5U) was added to the reaction. The reaction was 
placed in a PCR cycle machine with the PCR program: 
 
1 cycle: Denaturation  95°C for 2 minutes 
30 cycles: Denaturation  95°C for 30 seconds 
  Annealing 55°C for 30 seconds 
  Elongation 72°C for 1 minute 
1 cycle: Elongation 72°C for 7 minutes 
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 The primer sequences can be found in appendix 4. 
 
2.1.3 Agarose	  gel	  electrophorese	  
In agarose gel electrophoresis, different DNA fragments are separated according to their 
sizes. Since DNA is negatively charged, it will migrate to the positive pole when being in an 
electric field. Agarose in the gel disrupts the migration, and makes the bigger fragments 
migrate slower and thereby be more delayed in the gel. This creates a separation where the 
small fragments migrate further then the large fragments. A good separation depends on the 
sizes of the fragments to be separated and the concentration of agarose in the gel, which 
contributes to the agarose network. To visualize DNA, ethidium bromide is added in the 
agarose gel. It intercalates with double stranded nucleotides and makes the DNA visible as 
bands in ultraviolet light (UV-light). Prior to loading, the samples are mixed with loading 
buffer containing glycerol, which makes the samples sink to the bottom of the wells.  
To know the sizes of the bands, a molecular weight standard with fragments with known 
sizes is used. 
 
Procedure: 
In this thesis, 1% agarose gels were used. Agarose powder (final concentration of 1%) was 
mixed with Tris-acetate-EDTA (TAE) buffer (1x) and the reaction mix was heated until the 
agarose had melted completely. When the solution had cooled down to approximately 50°C, 
ethidium bromide was added (final concentration of 0,5 µg/ml). The gel solution was poured 
into a gel-casting tray and a comb was inserted into right place to make the wells. When the 
gel had solidified, the comb was removed and TAE (1x) buffer was added until covering the 
gel. Before the samples were loaded into the wells, a 6x loading dye (final 1x) was added to 
the samples. The gel was run at 80V, 240mA for 40 minutes, and finally the DNA fragments 
were visualized in UV-light in a gel doc (GeneGenius Gel Light Imaging System, Syngene). 
 
2.1.4 Restriction	  enzyme	  digestion	  
A restriction enzyme binds to a specific DNA sequence and cleaves the phosphodiesterbond 
holding the nucleotides together. Different restriction enzymes recognize different DNA 
sequences and generates either a blunt end or a cohesive end at the position for cleave. A 
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which strand the unpaired nucleotides are positioned, the cohesive ends can be with a 5´- or a 
3´overhang. 
 
In this thesis restriction enzymes were used to digest DNA fragments to get complementary 
ends before ligation. It was also used to verify plasmids after maxiprep or miniprep 
(described in section 2.1.12). 
 
Procedure: 
10x FastDigest buffer (final 1x), DNA (1 µg) and MQ-water (up to 20 µl) were mixed and 
FastDigest restriction enzyme(s) of interest was added (1U). The mix was incubated in 37°C 
for one hour, if the DNA fragments not were subject for further use, otherwise, the solution 
was incubated in 37°C overnight. The reaction was terminated by adding loading buffer or by 
heating the samples to the temperature required for inactivation of the enzyme (specified by 
the manufacturer).  
 
2.1.5 Blunting	  
Blunting is a process that converts cohesive ends to blunt ends. Nucleotides are incorporated 
in overhangs by a polymerase. 
 
In this thesis a Klenow fragment was used as polymerase. A Klenow fragment is a DNA 
polymerase, which has lost its 5´à3´ exonuclease activity. Meaning that it can fill a 
5´overhang, but it cannot remove it.  
 
Procedure: 
Nucleotides (to a final concentration of 0,5 µM) and Klenow fragment (3U) was added to the 
inactivated restriction enzyme solution (final volume 20 µl). The reaction mix was incubated 
at 37°C for 20 minutes, and then the Klenow fragment was heat-inactivated at 75°C for 10 
minutes.  
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2.1.6 Dephosphorylation	  of	  DNA	  
After restriction enzyme digestion (described in section 2.1.4) and blunting (described in 
section 2.1.5), the DNA is left with a free phosphate group on each strand. The phosphate 
group can be used to create a phosphodiesterbond and join two DNA fragments together by 
ligation (described in section 2.1.9). 
 
To prevent an already digested plasmid to re-ligate in the ligation process, the phosphate 
groups on the vectors are removed by a phosphatase prior to ligation. The fragment is then 
free to be joined to the insert of interest, which provides the phosphatase groups.  
 
Procedure: 
FastAP Thermosensitive Alkaline Phosphatase (Thermo Scientific) (1U) was added to the 
reaction mixture after inactivation of the restriction enzymes or the Klenow fragment. This 
was incubated at 37°C for 10 minutes before the phosphatase was inactivated at 80°C for 5 
minutes.  
 
2.1.7 Purification	  of	  DNA	  from	  gel	  or	  solution	  
Isolation of one DNA fragment from a mix containing several fragments is carried out by 
running an agarose gel (described in section 2.1.3), collecting the fragment of interest from 
the agarose and purifying the DNA from the components in the gel. The piece of gel 
containing the fragment of interest is cut out from the gel while visualizing the DNA in UV-
light. The DNA is purified from the gel by a spin-system kit from Promega (Wizard® SV Gel 
and PCR clean-up system). The kit contains a binding buffer that is used to make the DNA 
less soluble and more prone to bind to a silica membrane provided by the kit. With the DNA 
bound to the membrane, other components can easily be washed away by centrifugation. The 
DNA is eluted and collected from the membrane in a low-salt buffer, which makes the DNA 
soluble and loses the capacity to bind to the silica membrane. The same kit can be used to 
purify DNA from solution.  
 
In this thesis DNA purification from gel was used after restriction enzyme digestion to purify 
DNA fragments prior to ligation. DNA purification from solution was used after PCR 
reaction and before transformation to remove components used in ligation, like PEG and 
ligase.  
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Procedure: 
The protocol recommended from Promega (The Wizard SV Gel and PCR Clean-Up System 
kit) was followed. 
 
2.1.8 Measurement	  of	  DNA	  concentration	  by	  Nanodrop	  
Concentration and purity of nucleic acids can be determined by measuring absorbance at 
different wavelengths. By measuring absorbance at 260 nm, the concentration of DNA and 
ribonucleic acid (RNA) can be determined, as the nucleic acids absorb light in this 
wavelength. Proteins absorb light at 280 nm and organic compounds absorb light at 230 nm. 
The ratio between 260/230 and 260/280 shows the purity of a nucleic acid solution, since it is 
the amount of proteins and organic compounds present in ratio of nuclei acids.  
 
The DNA concentration was measured before ligation (described in section 2.1.9) to get the 
right ratio of insert and vector. It was also measured after maxiprep and miniprep (described 
in section 2.1.12) to determine the DNA/RNA concentration prior to further work. 
 
Procedure: 
The nucleic acids solution (2 µl) was applied on a micro volume UV-Vis spectrophotometer 
(Nanodrop 2000 c spectrophometer, Thermo Scientific). Before measurements the 
spectrophotometer was calibrated with the solution the nucleic acid was solved in. The 
NanoDrop ND-2000 software calculated the concentration and ratios of the sample.  
 
2.1.9 Ligation	  
Ligation is a process where two DNA fragments are joined together by an enzyme, ligase. 
The fragments are joined by a phosphodiester bond between a 3´ hydroxylgroup and a 5´ 
phosphoryl group. 
The right molar ratio between insert and vector is critical to get a successful ligation.  
The ratio (R) of insert/vector can be calculated by; 
 ng   of  insert bp  of  insertng  of  vector bp  of  vector = R 
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The ligase used in the ligation requires right physiological conditions to work properly, 
which is obtained through a buffer containing the components needed, like adenosine 
triphosphateadenosine triphosphate. A transient connection between nucleotides in cohesive 
ends will increase the possibility for the ligase to connect the nucleotides together. Blunt ends 
do not get a transient connection, but some difference in the environment can help to get a 
successful ligation. PEG is a crowding agent that reduces the solvent available for the 
fragments and the ligase, which increases the possibility for the fragments to align and being 
ligated together by the ligase. By using a higher amount of ligase the possibility for the 
aligned fragments to be joined together can be further increased.  
 
Procedure: 
The molar ratio used was 1:3 or 1:6 (vector:insert), with 70 ng vector. Amount insert was 
calculated by the equation above. 
 
Blunt end ligation: 
Vector and insert were mixed with 10x T4 DNA ligase buffer (final concentration 1x), 50 % 
PEG 4000 solution (final concentration 5%) and MQ-water (to get a 20 µl reaction). T4 DNA 
ligase was added (5 U), and the reaction was incubated at 16°C overnight. The T4 DNA 
ligase was not inactivated, since inactivation in the presence of PEG could inhibit the 
electrotransformation (section 2.1.11) that is following ligation.  
 
Sticky end ligation: 
Vector and insert were mixed with 10x T4 DNA ligase buffer (final concentration 1x) and 
MQ-water (to get a 20 µl reaction). T4 DNA ligase was added (1 U) and the reaction was 
incubated at 16°C for one hour. The T4 DNA ligase was inactivated at 70°C for 5 minutes. 
The ligation mix was not purified before transformation. 
 
2.1.10 Production	  of	  Electrocompetent	  E.Coli	  XL1.Blue.	  
Prior to electrotransformation the bacteria need to gain the ability for uptake of exogenous 
DNA, called to achieve competence. To gain competence, the bacteria are grown in lysogeny 
broth (LB) medium to an optical density (OD) of OD600nm=0,94. Afterwards the bacteria 
are washed several times to remove all traces of LB medium as components from the medium 
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can cause an electric flow through the solution and reduce the viability of the bacteria upon 
electroporation.  
 
Competent bacteria are used to amplify a plasmid of interest. Antibiotic resistance is used to 
sort between bacteria with or without the plasmid of interest. The plasmids are carrying an 
antibiotic resistance gene and only the bacteria that have taken up the plasmid will survive in 
a medium with the specific antibiotic. Since it is critical that the competent bacteria do not 
carry an antibiotic resistance without the plasmid of interest, the bacteria are examined for 
antibiotic resistance prior to the production of competent bacteria. 
 
Procedure: 
Prior to the production, the bacteria were tested for growth on LB-plates containing 
kanamycin, ampicillin or no antibiotics.  
Only colonies that did not grow in medium containing kanamycin or ampicillin were chosen 
to proceed.   
 
On day 1; one colony was inoculated in LB medium (20 mL/litre final culture) (recipe in 
appendix 3), called “pre-culture” and incubated over-night in 37°C while shaking at 200-250 
rpm. On day 2; the pre-culture was inoculated in pre-warmed LB medium (1 litre/20mL pre-
culture) and grown in 37°C while shaking at 200-250 rpm. Every 10 minutes, the optical 
density (OD) at 600 nm was measured. When OD reached 0,94, the culture was placed on 
ice-bath for 15 minutes. The bacteria were harvested by centrifugation, 4000 x g at 4oC for 5 
minutes, and the bacterial pellet were washed twice with cold water (200mL/litre culture) and 
once with cold 10% glycerine (50 mL/litre culture) (recipe in appendix 3). Finally, the 
bacteria were resuspended in glycerol-yeast extract-tryptone (GYT) medium (4mL/litre 
culture) (recipe in appendix 3), aliquoted into tubes on an ethanol/dry-ice bath and stored at -
80°C. 
	  
2.1.11 	  Electrotransformation	  of	  E.Coli	  XL1-­‐blue	  cells	  
Transformation is a process in which bacteria take up genetic material from the environment 
with high efficiency. In electrotransformation, the genetic material is introduced with help of 
an electric field/pulse. Purification of DNA (described in section 2.1.7) is necessary prior to 
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electro-transformation if the plasmid has been created by blunt-end ligation in due to the 
presence of PEG that interferes with electrotransformation.  
 
Procedure: 
Cuvettes were put on ice and Super Optimal broth with Catabolite repression (SOC) medium 
(recipe in appendix 3) was pre-warmed to 37°C.  The competent bacteria were thawed on ice. 
Plasmid solution (1 µl with the concentration 1ng/µl to 50 µl bacteria) or ligation solution (1-
2 µl to 50 µl bacteria) were mixed with electro-competent bacteria and transferred to 2 mm-
cuvettes. The cuvettes were pulsed at 900V/(mm gap on the cuvette) (ECM 399 
electroporation system BTX®, Harvard apparatus), and pre-warmed SOC medium 
(500µl/50µl bacteria) was added immediately after the pulse. The bacteria mix were 
transferred to Eppendorf tubes and incubated in a shaker at 37°C, 225 rpm for one hour. The 
bacteria mix were transferred to LB agar plates (150 µl/plate) (recipe in appendix 3) with 
appropriate antibiotics (kanamycin 25 µg/ml or ampicillin 50 µg/ml) and incubated at 37°C 
overnight. The rest of the transformed bacteria were kept in the fridge until the day after. If 
no colonies appeared on the plates, the rest of the bacteria (kept overnight in the fridge) were 
transferred to a new LB agar plate, as described above. 	  
2.1.12 Isolation	  of	  plasmid	  DNA	  	  
Plasmid DNA was isolated from bacterial cultures as miniprep (QIAprep Spin Miniprep Kit, 
Qiagen) or maxiprep (EndoFree Plasmid Maxi Kit, Qiagen).  
 
Plasmid	  purification	  by	  miniprep	  
The QIAprep Spin Miniprep kit from Qiagen is based on a spin-system. A buffer containing 
chaotropic salts distrupt the hydrogen bond between water and nucleic acids, which makes 
the nucleic acids less soluble and more prone to binding to a silica membrane. Proteins and 
other components that do not bind to the silica membrane during these conditions are 
removed during several washing steps. To elute the nucleic acids, a buffer with low salt 
concentration is used to make the nucleic acids soluble. Miniprep is used when a low amount 
of the plasmid is needed.  
 
In this thesis miniprep was used to verify clones after electrotransformation (described in 
section 2.1.11).  
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Procedure: 
After transformation, one colony was transferred to LB medium (3-5mL) with appropriate 
antibiotics (25 µg/ml of kanamycin or 50 µg/ml of ampicillin) and grown for 16-18 h at 37°C 
in 225 rpm. Cells were harvested by centrifugation at 6800 xg for 3 minutes at room 
temperature (RT) and miniprep was performed according to the manufacturers 
recommendations in the kit protocol from Qiagen. 
 
Plasmid	  purification	  by	  maxiprep	  
Maxiprep can be performed to get a higher yield of plasmids than possible from miniprep.   
The maxiprep kit from Qiagen is designed to isolate DNA plasmids from 200 mL LB 
medium culture grown overnight in Erlenmeyer bottles. The purification is based on an anion 
exchange resin with high affinity for plasmids. The negative phosphate groups on the DNA 
bind to the positive groups on the surface of the resin. To make the DNA bind to the resin, a 
buffer with low salt concentrations is used in the binding step. Buffer with medium salt 
concentration is used to wash away proteins, RNA and other components. The DNA is eluted 
in a buffer with high salt concentrations, the positive groups at the resin make stronger bonds 
with the salt and the DNA is eluted. To remove the salt in the elution buffer, DNA is 
precipitated with isopropanol and the DNA pellet is washed in 70% ethanol prior to 
resuspension in Tris-EDTA (TE) buffer (400 µl). 
 
Procedure: 
After transformation, one colony was transferred to LB medium (200 mL) with appropriate 
antibiotics (with 25 µg/mL of kanamycin and 50 µg/mL of ampicillin) and grown for 16-18 h 
at 37°C for 225 rpm.  The bacteria were harvested in 6000 xg for 15 minutes in 4°C. The 
maxiprep was performed as recommended in the protocol from the manufacturers. 
 
2.1.13 	  Sequencing	  
DNA sequencing is a technique used to determine the exact order of nucleotides in a DNA 
molecule.   
 
Sequencing was performed after generation of new vectors to verify the sequences in the 
transition between the vector and the insert. 
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Procedure: 
A company called GATC Biotech (http://www.gatc-biotech.com/en/index.html) performed 
the sequencing. Samples were prepared for sequencing by mixing template-solution (5 µl in 
concentration; 80-100 ng/µl) with primer (5 µl of 5 pmol/µl) in Eppendorf tubes (primer 
sequences can be found in appendix 4). The tubes were marked with barcodes and sent to 
GATC Biotech. The results were analysed in the sequencing program Geneious 
(http://www.geneious.com/).  
 
2.2 Mammalian	  cell	  work	  
A T-cell line was used in this thesis to perform subcellular localization and functional studies 
of CLEC16A. The main tool for the cell work in this study is transfection, which in this thesis 
is used either to overexpress a protein of interest by introduction of exogenous DNA (DNA 
plasmids) or knock down expression of the gene of interest, i.e. CLEC16A by introducing 
CLEC16A specific siRNA. 
 
The T cell line used was Jurkat TAg T cell line. Other group members have shown that the 
Jurkat T cell line expresses endogenous CLEC16A and that it can be knocked down when 
transfected by CLEC16A specific siRNA. In addition it is a cell-line suitable for transfection. 
 
Jurkat TAg T cell line 
The Jurkat TAg cell line is a derivative of the human T-cell leukemia Jurkat E6.1 cell line 
(www.atcc.com) stably transfected with the SV40 large T antigen (73). This T cell line is 
derived from peripheral blood from a human male with acute T cell leukaemia. It is rapidly 
growing and is suitable for transfection.  
 
2.2.1 Cell	  cultivation	  
Jurkat TAg cells were cultivated in Roswell Park Memorial Institute (RPMI) 1640 medium 
with fetal bovine serum (FBS, 10%) as serum supplement, penicillin/streptomycin (1%) to 
prevent bacterial growth, sodium pyruvate (1%) as energy source, non-essential amino acids 
(1%) and β-mercaptoethanol (0,05mM) as a reducing agent to prevent toxic oxygen radicals 
to be produced.  
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The cells were cultivated at a concentration of 0,3 x 106 cells/ml - 2 x 106 cells/ml at 37°C in 
5% CO2. Fresh media were added three times a week and the concentration did never exceed 
2.5 million cells/ml. Stocks of the cells were stored in liquid nitrogen and new cells were 
thawed every third month.  
 
2.2.2 Cell	  count	  
The cells were counted prior to all cell-experiments and when given fresh media. An 
automated cell counter (TC20™ Automated Cell Counter, Bio-Rad) was used to count both 
live and dead cells. 
 
Procedure: 
Resuspended cell suspension was transferred to a chamber slide (Counting Slides dual 
chamber for cell count, Bio-Rad) (10 µl/slide). To count both live and dead cells the 
resuspended cell suspension was mixed with trypan blue (1:1) before it was transferred to the 
slide (10µl/slide). The chamber slide was inserted into the cell counter, which calculated the 
amount of cells (and percentage of dead cells if trypan blue was used). 
 
2.2.3 Transfection	  of	  Jurkat	  T	  cells	  
Transfection is a common technique used to introduce exogenous DNA into mammalian 
cells. Transfection can also be used to knock down the expression of cell-endogenous genes 
by transfecting with a target-specific siRNA. 
 
Jurkat T cells are transfected by electroporation where a short intense pulse of an electric 
field is applied to the cells to increase the permeability of the cell membrane enabling 
external genetic material to pass.  
 
Procedure: 
The cells were counted and harvested (15 x106 cells/transfection) at 300 x g for 8 minutes at 
RT. The cells were washed twice with RPMI medium and resuspended in transfection 
medium (400 µl/transfection) (RPMI with 5% FBS, 1% non-essential-amino acids, 1% 
sodium pyruvate and 0,05mM β-mercaptoethanol). The cells were mixed with the DNA/RNA 
of interest (the amount of DNA/RNA was empirically determined for each plasmid/siRNA). 
The cell/DNA or cell/RNA mix was transferred to cuvettes (4mm) and incubated at RT for 15 
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minutes. The cuvettes were pulsed once with the current settings: 240V, 25ms. After the 
pulse, the cells were incubated at RT for 15 minutes. The cells were transferred to T-75 flasks 
with pre-heated (37°C) transfection medium (10ml/transfection) and incubated for 24 or 48 
hours at 37°C in 5% CO2. If the cells were cultivated for 48 hours, fresh medium was added 
after 24 hours to achieve a cell concentration of 0,9 x 106 cell/ml.  
 
2.2.4 Flow	  cytometry	  
Flow cytometry is a technology used to analyse the physical and chemical characteristics of 
particles in a fluid as it passes through a laser. It is routinely used for analysing expression of 
cell surface and intracellular molecules. Different detectors are placed to catch light scatter or 
emitted light from fluorescently labelled cells. In the light beam, forward scatter (FSC) and 
side scatter (SSC) are measured. FSC correlates with the diameter of the cells whereas SSC 
correlates with the density of the particle, i.e. the granularity of the cells.  
 
Pulsed cells (with no plasmid) were used to define single and living cells by gating as 
described in figure 2.2. In addition pulsed cells were used as a negative control for GFP. The 
following gating was performed: single cells were gated in a Forward Scatter (FSC) 
Areal/FSC Height plot (figure 2.2 A) and living cells were gated in a FSC areal/side scatter 
(SSC) areal plot (figure 2.2 B).  
 
 
Figure 2.2. Overview of cell gating in flow cytometry measurements. A) Single cells are gated in a 
forward scatter areal (FSC(A))/forward scatter height (FSC(H)) plot. B) The plot displays the single 
cells (R1) and R2 defines the living cells gated in FSC (A)/side scatter areal (SSC(A)) plot.  
 
To estimate the transfection efficiency of an experiment, one extra sample was added when 
transfection was performed. Cells were transfected with a plasmid expressing GFP (pEGFP-
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N3). Flow cytometry was used to analyse the percentage of GFP-positive (GFP+) cells after 
transfection. The percentage of GFP+ cells was determined in a population of single and 
living cells. The percentage was used as a measurement between transfections performed at 
different times.  
 
Procedure: 
Cells directly from suspension were analysed on flow cytometry (Attune acoustic focusing 
cytometer, Applied Biosystem by Life Technologies) (solutions used are listed in materials in 
appendix 2). 10 000 cells were analysed by flow cytometry for each transfection performed.  
 
2.2.5 Cell	  lysis	  
Radioimmunoprecipitation assay buffer (RIPA) (Pierce RIPA buffer, Bio-Rad) was used to 
make whole cell lysates. It contains Sodium dodecyl sulphate (SDS) that destroys the cell 
membrane, and it has a salt concentration that favours osmosis, meaning that the fluid in the 
cells are moving out to the extracellular environment. These properties together will lead to 
cell lysis. This procedure is performed to release the cell content and collect the proteins for 
further analysis, for instance for Western blotting.  
 
Procedure: 
The cells were counted and harvested by centrifugation at 300 x g for 8 minutes at RT. The 
cells were washed twice with phosphate buffered saline (PBS). All PBS was removed from 
cell pellet. The cells were either lysed directly or the pellet was stored at -20°C and lysed at a 
later time point.  
 
Protease inhibitor cocktail (PIC) was added to the RIPA buffer and the mix was added to the 
cell pellet (20 µl/million cells). The tube was vortexed until the pellet had been completely 
resuspended in the buffer. The tube was put on a rotator machine at 4°C for 1 hour and then 
centrifuged at 12 000 x g at 4°C for 15 minutes. The supernatant was transferred to a new 
ice-cold tube and stored at -80°C.  
 
2.3 Protein	  work	  
When transfecting Jurkat T cells with a plasmid, the proteins encoded by DNA on the 
plasmids will be expressed in Jurkat T cells. In this thesis the proteins that are expressed is 
	   33	  
analysed by Western blot analysis or by imaging technics (described in section 2.4). The 
subcellular localization is examined by either collecting proteins from different cellular 
fractions and detected them by Western blot analyse, or by visualize the cells by imaging. In 
this section, compartmental protein extracting and detecting on Sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS PAGE) and Western blot analysis are described.  
 
2.3.1 Compartmental	  protein	  extracting	  	  
By using buffers to change the environment for cell content, proteins located in different 
compartments in the cell can be separated and collected. A kit form Millipore 
(Compartmental Protein Extraction kit) sequentially extracts proteins from the nucleus, 
cytosol, membrane and cytoskeleton. After the extraction, the different fractions are analysed 
on a Western blot with organelle-specific antibodies to show the purity of each fraction. With 
pure fractions it is possible to identify the fraction a protein of interest is located in.  
 
This procedure was used for Jurkat T cells transfected with GFP/DDK-tagged CLEC16A-
plasmids to identify the fraction the overexpressed protein was localized in. Additionally, it 
was used in untransfected Jurkat T cells to identify the fraction for endogenous CLEC16A.  
 
Procedure: 
The protocol provided by the manufacturer (Millipore) was followed, with these extra steps; 
- The needle used in disrupting the cell membrane was with gauge 30 (26.5-29 were 
recommended in the protocol)  
- The incubation step with nuclear lysis buffer was repeated with a double amount of 
buffer the second time.  
 
2.3.2 Bradford	  assay	  for	  protein	  concentration	  determination	  
The same input of proteins should be applied on a gel when analysing proteins on SDS 
PAGE (section 2.3.3) and Western blot analysis (section 2.3.4). The protein concentration 
can be determined by performing Bradford assay. Coomassie blue, used in Bradford assay, is 
a dye that has different forms that is giving different colours to the solution. When proteins 
bind the form changes, hence the colour changes in the solution dependent on the protein 
concentration, which can be detected by measure OD at 595 nm in a spectrophotometer. 
Higher protein concentrations give rise to a stronger blue colour and a higher absorbance.  
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Procedure: 
Coomasssie blue dye (1 ml, Quick start Bradford 1X Dye reagent, Bio-Rad) was mixed with 
either bovine serum albumin (BSA, Bio-Rad) (0.5 µl, 1 µl, 2 µl, 4 µl or 8 µl of 2 mg/ml) or 
the samples with unknown concentration (2 µl). All samples were prepared in duplicates. The 
samples were vortexed before incubated for 15 minutes at RT. The absorbance was measured 
at 595 nm (Ultraspec 2100 pro, Amersham Bioscience). 
 
2.3.3 	  SDS	  PAGE	  
SDS PAGE separates proteins according to their mobility in polyacrylamid gels. SDS 
denatures and linearizes proteins and gives them an evenly distributed negative charge in a 
charge-to-mass ratio. This makes the separation only dependent on the molecular mass of the 
proteins. When an electrical field is applied, the proteins will migrate towards the positive 
pole due to its negative charge. The smaller proteins will migrate further than the bigger ones 
since they are less impaired by the polyacrylamide in the gel. 
 
The percentage of polyacrylamide can vary between gels. High percentage of polyacrylamide 
will give more inhibition for the migrating proteins and will give a better separation of small 
proteins. In contrast, low percentage of polyacrylamide will give less inhibition and a better 
separation of larger proteins. In gradient gels the percentage will vary throughout the gel with 
low percentage nearest the negative pole and high percentage at the positive pole. Gradient 
gels can be used to get a good separation of both small and large proteins at the same time. A 
protein marker, with proteins of known sizes, is used to determine the size of the proteins of 
interest.  
 
In this thesis SDS PAGE was performed to separate proteins after cell lysis (section 2.2.5) or 
cellular fractionation (section 2.3.1). To detect the protein(s) of interest, Western blotting was 
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Procedure: 
Precast gels (Bio-Rad); gradient 4-12%, 10% or 7,5% polyacrylamid gels were used. The gel 
was placed into the electrode assembly (Criterion™ cell, Bio-Rad) and the inner chamber 
was filled with running buffer (1x, recipe see appendix 3) until the wells were completely 
covered by buffer. The lower chamber was filled with the same buffer until the buffer 
covered the bottom of the gel. Loading dye with SDS (recipe, see appendix 3) was applied to 
the samples and incubated for 5 minutes at 95°C. The samples and the molecular standard 
were applied to the wells. The gel was running at 150 V and maximum milli-Ampere 
(mAmp) for 15 minutes followed by 200 V and maximum mAmp for approximately 45 
minutes.  
 
2.3.4 Western	  blotting	  
Western blotting is a technique that uses antibodies to detect specific proteins in a sample. 
After SDS PAGE (section 2.3.3), the separated proteins are transferred to a polyvinylidene 
fluoride (PVDF) membrane by electroblotting. The proteins are moving in an electric field 
towards the positive pole. They are pulled from the gel into the membrane where they bind 
through non-specific hydrophobic interactions. After the electro-transfer, the membrane is 
blocked with a protein-rich solution to inhibit un-specific binding of antibody to the 
membrane. The membrane is then incubated with a primary antibody specific against the 
target protein. This is followed by incubation with a secondary antibody, recognizing the 
species-specific part of the primary antibody. The secondary antibody is also linked to an 
enzyme, horseradish peroxidase (HRP), which catalyses the oxidation of a chemiluminescent 
substrate. The product of the reaction emits light, where the amount of light corresponds to 
the amount of HRP present, hence the amount of protein of interest present. The light can be 
strengthened in a process called enhanced chemiluminescence (ECL), which amplifies the 
signal by 1000-fold and makes it detectable. To detect the light signal, a film is placed over 
the membrane and the light emitted from the HRP-bound secondary antibody is captured on 
the film. The signals on the film are visualized and fixed by developing the film. 
After use, the membrane is wrapped in plastic and stored at 4°C and can be stripped, i.e. 
removing both primary and secondary antibodies with a stripping blot buffer, enabling 
reprobing of the membrane with new antibodies.  
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Procedures: 
Transfer from gel to membrane 
After SDS PAGE, the gel was washed in distilled water (dH2O) and put in cold transfer 
buffer (recipe in appendix 3). The PVDF membrane (Immun-Blot® PVDF membrane, Bio-
Rad) was activated in methanol for 15-30 seconds, washed with dH2O and put in cold 
transfer buffer. Two extra thick filters were soaked in cold transfer buffer. One filter was 
placed in the blotting apparatus with the membrane on the top. The gel was placed on top of 
the membrane and lastly the second filter was placed on top of the gel. Air bubbles were 
pressed out from each layer, and the lid from the blotting apparatus was placed on top of the 
assembly. The blot was run at 1 mAmp/cm3, 50 V for one and a half hour (Amersham ECL 
Semi-Dry Blotters TE 77 PWR, Amersham Bioscience).  
 
Antibody detection of protein of interest  
The membrane was blocked with 4% skimmed milk/Tris-Buffered Saline with Tween 20 
(TBS/T) (recipe in appendix 3) at RT for one hour. Primary antibody was diluted in 4% 
skimmed milk/TBS/T (according to the manufacturer, the exact dilution was determined 
empirically for each antibody) and incubated with the membrane over night at 4°C on a 
shaker. The membrane was washed 3x20 minutes at RT with TBS/T (recipe in appendix 3) 
before incubation with secondary antibody. Secondary antibody was diluted (according to 
manufacturer) in 4% skimmed milk/TBS/T and incubated with the membrane for one hour at 
RT. The membrane was washed 3x20 minutes in TBS/T. Super-signal solutions (ratio 1:1, 
SuperSignal ® West pica Chemiluminescent substrate, Thermo Scientific) were applied drop 
wise over the membrane to completely cover the membrane. The membrane was incubated 
for 5 minutes with the super-signal solution and placed in a developer cassette. A film was 
incubated in the cassette with the membrane and was developed using Curix 60 from AGFA 
HealthCare. 
 
Stripping of PVDF membrane  
The membrane was reactivated in methanol for 15 seconds, rinsed in dH2O and washed once 
in TBS/T. The membrane was boiled in the microwave own for a few seconds with 10x SDS 
running buffer. The membrane was washed 3x20 minutes with TBS/T, and stripping buffer 
(Restore Western Blot Stripping Buffer, Thermo Scientific) was added to the membrane. It 
was incubated for 15 minutes at RT and then washed 3x20 minutes with TBS/T. The 
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membrane was then blocked for one hour in 4% skimmed milk and incubated with a new 
antibody as described above (“Antibody detection of protein of interest“).  
 
2.4 Imaging	  
The subcellular localization of CLEC16A and its function in endosomal distribution were 
investigated by the imaging techniques, confocal microscopy and Image Stream. In this thesis 
the proteins are visualized by being fused with a fluorescent molecule (as GFP or mCherry) 
or by being targeted by antibodies, which are coupled with a fluorescent molecule 
(immunostaining described in section 2.4.1), prior to confocal microscopy and Image Stream. 
This section describes these imaging techniques, in addition the method for visualizing 
proteins prior to imaging is described. 
 
2.4.1 Immunostaining	  of	  cells	  	  
In immunostaining, a primary antibody is used to target a specific protein in the cell. 
Secondary antibody is used to target the primary antibody and is commonly coupled with a 
fluorescence molecule enabling visualization of the signals in for example a fluorescence 
microscope. In the current thesis, paraformalaldehyd (PFA) was used to fix the cells, to 
preserve the cell structure. Saponin was used to permeabilize the cells, to make it possible to 
target intracellular proteins. Saponin is a gentle detergent that makes small pores in the cells 
without destroying the membrane. To preserve the permeability, saponin needs to be applied 
in every step after the permeabilization.  
 
In this thesis, immunostaining was used in co-localization studies, by targeting the DDK tag 
on CLEC16A, and to visualize the organelle markers LAMP1 and TGN46. In addition, it was 
used in endosomal distribution studies to target lysosomes by the marker LAMP1. The 
samples were visualized by confocal microscopy or Image Stream analyses (the latter was 
performed by Ingvild Sørum Leikfoss, PhD student in the lab). 
 
Procedure: 
Jurkat Tag cells (1,5 millions for confocal microscopy, 4 millions for Image Stream) were 
stained in their culture medium with Hoechst (1 mg/ml in a dilution of 1:1000) for 20 
minutes in 37°C, 5% CO2, then harvested by centrifugation, 300 xg for 8 minutes at RT. The 
cells were washed once with RPMI medium.  
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Preparation of samples for confocal microscopy: 
The cells were resuspended in 75 µl RPMI/millions cells. The cells were applied on slides 
coated with poly-L-lysine (Polysine™ microscope slides, VWR). The cells on the slides were 
incubated for 10 minutes in RT to make the cells attach to the slides. The medium was 
removed and 3% PFA in PBS (200 µl) was applied on the cells. The cells were fixed for 
maximum 10 minutes at RT. The PFA was removed, and the cells were washed twice with 
PBS/2%FBS (200 µl). The cells were then permeabilized with PBS/0,05% Saponin/0,25% 
BSA (200 µl) for 5 minutes. After removal of the saponin-solution, the cells were washed 
twice with PBS/0,05% Saponin/2%FBS (200 µl) and blocked with 
PBS/0,05%Saponin/0,25% BSA (200 µl) for 20 minutes at RT. The blocking solution was 
removed and the cells were incubated with primary antibody (concentration of the antibodies 
was empirically determined for each antibody guided by the manufacturers 
recommendations) diluted in PBS/0,05% Saponin/0,25% BSA (100 µl) for one hour. The 
antibody solution was removed and the cells were washed three times with PBS/0,05% 
Saponin/0,25%BSA (200 µl). Further the cells were incubated with secondary antibody 
diluted (after manufacturers recommendations) in PBS/0,05% Saponin/0,25% BSA (100 µl) 
for one hour in RT. The cells were washed three times and left to nearly dry before mounting 
media (35 µl) were applied on top of the cells. A coverglass (Cover glass thickness no 1, 
VWR) was put over the mounting media (SlowFade® Gold antifade reagent) and nail polish 
was used to seal the edges.   
 
Preparation of samples for Image Stream analyses 
The cells were resuspended in 2% PFA in PBS (200 µl), transferred to a cone shaped 96 well 
plate and fixed for maximum 10 minutes at RT. The PFA was removed, and the cells were 
washed twice with PBS/2% FBS (200 µl). The cells were permeabilized with PBS/0,05% 
Saponin/0,25% BSA (200 µl) for 5 minutes. The saponin solution was removed, and the cells 
were washed twice with PBS/0,05% Saponin/2% FCS (200 µl) and blocked with PBS/0,05% 
Saponin/0,25% BSA (200 µl) for 20 minutes in RT. The medium was removed, and the cells 
were incubated with primary antibody diluted (the concentration of antibodies was 
empirically determined for each antibody prior to the immunostaining of cells) in PBS/0,05% 
Saponin/0,25% BSA (200 µl) for one hour. The antibody solution was removed and the cells 
were washed three times with PBS/0,05% Saponin/0,25% BSA (200 µl) before they were 
incubated with secondary antibody diluted (after manufacturers recommendations) in 
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PBS/0,05% Saponin/0,25% BSA (200 µl) for one hour in RT. The cells were washed three 
times in PBS/0,05% Saponin/0,25% BSA (200 µl) before they were resuspended in PBS with 
0,05% sodium azide (120 µl). 
	  
2.4.2 Confocal	  scanning	  laser	  microscopy	  
Confocal microscopy is a technique used to achieve high-resolution optical images with 
depth-selectivity. The main difference between confocal microscopy and common 
fluorescent microscopy is the ability to remove out-of-focus light. The result is that light 
above and beneath the focus plane is removed through a pinhole (74).  
Confocal microscopy enables specific cell structures and proteins (dependent on target for 
antibody) to be detected and transformed into high-resolution images.  
High-energy lasers excite the fluorescent molecules at different wavelengths. Since 
fluorescent molecules excites at a specific wavelength, it is possible to label various targets in 
the same cell with different fluorochromes and use different lasers to excite these molecules. 
With excitation means that electrons “jump” to a higher energy state, and when falling back 
to ground state they emit light that can be detected. The energy difference between these 
states determines the wavelength of the emitted light. Different detectors are recording the 
emitted light from the various excited fluorochromes. The signals from the different detectors 
can then be gathered and transformed into an image. 
 
Procedure: 
The samples were obtained from transfected Jurkat T cells with the plasmid(s) of interest 
after 24 h or 48 h cultivation. If the samples not were subject for immunostaining (section 
2.4.1), the protocol for immunostaining was followed to the step with fixation of cells with 
PFA. After fixation, the cells were nearly dried on the poly-L-lysine coated glass-slide before 
mounting medium (SlowFade® Gold antifade reagent) was applied (35 µl). A cover glass 
was put on top and the edges were sealed with nail polish. The samples were stored at 4°C. 
 
Two confocal microscopes were used in this thesis, one located at core facility on Gaustad 
and the other one at the Imaging Platform at the department of Bioscience. Both microscopes 
were the same model, Olympus FV1000/BX61. The objectives used were PLAPO 60X (NA 
1,40) or UPLSAPO 60X (NA1,35), both oil based. The images were obtained in size 
1024x1024 pixels. For each sample, hundreds of cells were analysed and 5-10 images were 
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taken for each sample for more accurate analyses. The analyses of the endosomal distribution 
were performed without knowing which group the samples belonged in (overexpression, 
knock-down or controls).  	  
2.4.3 Image	  Stream	  
Image stream is an instrument combining flow cytometry and fluorescence microscopy 
analyses. In image stream, a large amount of cells is analysed and the instrument software 




The samples were obtained from transfected Jurkat T cells with the plasmid(s) of interest 
after 24 h or 48 h cultivation. If the samples not were subjected for immunostaining (2.4.1), 
the protocol for immunostaining was followed to the step with fixation of cells. After 
fixation, the cells were resuspended in PBS with natrium azide (0,05%) and stored at 4°C. 
 
PhD student Ingvild Sørum Leikfoss ran the samples on the Image Stream and did the data 
analysis using IDEAS software.  	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3 Results	  
The main purpose for this thesis was to find the subcellular localization of CLEC16A in 
Jurkat T cells and further to evaluate the possible function of CLEC16A in endosomal 
distribution in the same cells. 
 
The number experiments performed in each case is stated in the figure legend. Both the result 
from subcellular localization and endosomal distribution will be verified and quantified by 
Image Stream analyses to ensure that the observed pattern not is specific to only the 
subpopulation studied by confocal microscopy.  
 
3.1 Plasmid	  construction	  
In order to perform the necessary experiments to study CLEC16A localization and function 
in Jurkat T cells, a toolbox with different CLEC16A expression plasmids was required. The 
sub-cloning of the plasmids needed is described in this section. However, the plasmids 
available in the laboratory are not described (only listed in materials in appendix 2).  
 
The N- and C-terminal side of a protein can have different roles of importance for the 
function and localization, possible leading to different outcome of the localization when a tag 
is added on the C-terminal in contrast to the N-terminal side of a protein. To visualize the 
subcellular localization of CLEC16A by confocal microscopy, plasmids expressing GFP-
tagged CLEC16A were constructed. Since GFP is a relatively large protein (approximately 
27 kDa), there was a possibility that the localization of CLEC16A could be altered when it 
was fused to the GFP-protein. Since the importance of N- or C-terminal side of CLEC16A 
not was determined, two plasmids were constructed, one with GFP at the C-terminus of 
CLEC16A and one with GFP at the N-terminus of CLEC16A. The different gene construct 
will be referred to as CLEC16A-GFPC and GFPN-CLEC16A, respectively.   
 
To generate a control plasmid for pCMV6-CLEC16A-MYC-DDK (available in the 
laboratory, see materials in appendix 2) an empty vector containing all elements except 
CLEC16A-MYC-DDK cDNA was generated, i.e. pCMV6-empty. 
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3.1.1 Sub-­‐cloning	  of	  GFP-­‐tagged	  CLEC16A	  
To create the GFP-tagged CLEC16A constructs, we used the following plasmids: pCMV6-
CLEC16A-MYC-DDK, pEGFP-N3 and pEGFP-C1. All strategies ensured the right reading 
frame of the inserted cDNA, and we tried to minimize the length of the linker between GFP 
and CLEC16A. 
 
To generate pCMV6-CLEC16A-GFPC two strategies were first created. GFP was amplified 
by PCR from pEGFP-N3 by primer combination 1 (strategy 1) or combination 2 (strategy 2) 
(primer sequences in appendix 4). 
 
Generation	  of	  plasmid	  expressing	  CLEC16A-­‐GFPc	  
Strategy 1: Forward primer for PCR of GFP from pEGFP-N3 contains a new NotI site 
upstream of the GFP gene and the reverse primer includes the stop codon from GFP in the 
vector. After PCR amplification of GFP, the PCR product was digested with NotI and ligated 
into the NotI/PmeI sites of pCMV6-CLEC16A-MYC-DDK, replacing MYC-DDK with GFP 
(figure 3.1 A). 
 
Strategy 2: For PCR of GFP from pEGFP-N3, the same forward primer as in combination 1 
and a reverse primer that anneals to pEGFP-N3 downstream of the GFP stop codon covering 
a vector sequence with a NotI site were used. After PCR amplification of GFP, the PCR 
product was digested with NotI and ligated into the NotI site of pCMV6-CLEC16A-MYC-
DDK (figure 3.1 B).  
 
However, none of these two strategies did work in practice to generate a plasmid containing 
cDNA for CLEC16A-GFPC and two new strategies were created, strategy 3 and 4. They were 
performed in parallel to each other to generate C-terminally GFP-tagged CLEC16A.  
 
Strategy 3: To generate pCMV6-CLEC16A-GFPc: pEGFP-N3 was digested with NotI and 
SmaI to cut GFP out of the vector. This fragment was blunted and inserted into a blunted NotI 
site in pCMV6-CLEC16A-MYC-DDK (figure 3.2 A), replacing MYC-DDK with GFP.  
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Strategy 4: To generate pEGFP-N3-CLEC16A: pCMV6-CLEC16A-MYC-DDK was 
digested with EcoRI and NotI to cut out CLEC16A. The fragment was blunted and inserted 




Figure 3.1 Generation of pCMV6-CLEC16A-GFPC - schematic overview of strategy 1 and 2. 
Strategy (A) 1 and (B) 2 were tested to generate pCMV6-CLEC16A-GFPc. The CLEC16A cDNA is 
illustrated in orange and the GFP cDNA in green. The procedures and restriction enzymes used are 
indicated in the figure. The sequence of the primers distinguishes the two strategies as indicated in the 
result section above. The primer sequences are found in appendix 4. 
 
Both strategy 3 and 4 gave rise to colonies containing a construct with GFP in the right 
orientation. From earlier work by other group members, pCMV6-CLEC16A-MYC-DDK has 
not been able to be used for transfection in Raji B cells. Additionally, we have observed that 
bacteria transformed with pCMV6-CLEC16A-GFP grow very slowly, making it difficult to 
isolate DNA from these cultures with sufficient concentrations needed for further use in 
transfection. Therefore, the construct from strategy 4 was chosen for further work and the 
plasmid is referred to as CLEC16A-GFPC in the rest of the thesis.  
 
Generation	  of	  plasmid	  expressing	  CLEC16A-­‐GFPN	  
To generate GFPN-CLEC16A (strategy 5): CLEC16A was obtained in same manner as 
described in strategy 4. The blunted fragment was inserted into SmaI and blunted XbaI in 
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pEGFP-C1-SUMO, to replace SUMO with CLEC16A (figure 3.2 C). A construct containing 
the right orientation of CLEC16A was obtained and the plasmid is referred to as GFPN-




Figure 3.2. Generation of pCMV6-CLEC16A-GFPC, pEGFP-N3-CLEC16A and pEGFP-C1-
CLEC16A: Strategy (A) 3 and (B) 4 were developed for generating plasmids encoding CLEC16A-
GFPC and (C) strategy 5 was developed for generating plasmids encoding GFPN-CLEC16A. The 
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CLEC16A cDNA is illustrated in orange, the GFP cDNA in green and the SUMO cDNA in blue. 
Procedures, restriction enzymes and plasmids used are indicated in figure. 
 
All GFP-tagged CLEC16A plasmids obtained from sub-cloning were verified by restriction 
enzyme digestion and sequencing.  
 
3.1.2 Cloning	  of	  pCMV6-­‐empty	  
The restriction enzymes BamHI and PmeI removed CLEC16A-MYC-DDK from pCMV-




Figure 3.3. Schematic overview of the strategy to generate pCMV6-empty. The CLEC16A cDNA 
is illustrated in orange. The procedures, plasmid and restriction enzymes used to generate pCMV6-
empty are indicated in the figure.  
 
The pCMV6-empty plasmid was verified by restriction enzyme digestion and sequencing.  
 
3.1.3 Expression	  of	  CLEC16A	  constructs	  in	  Jurkat	  T	  cells	  	  
After the plasmid had been verified on DNA level, it also needed to be verified at protein 
level. The plasmids were transfected into Jurkat T cells and the cells were harvested and 
lysed. The protein concentration in the whole cell lysate was measured by Bradford assay and 
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the same amount of protein from all samples to be compared, was applied on an SDS 
polyacrylamide gel. The fused proteins were analysed using Western blotting with antibodies 
against GFP or DDK.  
 
Expression	  of	  CLEC16A	  fused	  with	  GFP	  
Before investigating the expression on the GFP-tagged CLEC16A, the optimal amount of 
plasmids for transfection into Jurkat T cells was determined by testing a range between 1-20 
µg. Optimal amount was defined as when the overexpressed protein easily could be detected. 
Flow cytometry analyses were performed 24 h and 48 h after transfection of GFP-tagged 
proteins to identify the amount plasmids and time for harvesting, for optimal expression (data 
not shown). The optimal amount of plasmid was 5 µg for CLEC16A-GFPC and 3 µg for 
GFPN-CLEC16A. For both plasmids it were optimal for the cells to be harvested 48 hours 
after transfection. 
 
Further, the proteins were confirmed to express the fused protein in the right size by Western 
blot analyses. Jurkat T cells were transfected with plasmids encoding GFP-tagged CLEC16A 
or GFP (positive control). The lysates were treated as described above, but to ensure a 
distinct band on the positive control, a smaller amount of proteins were applied from the 
lysate from GFP-transfected cells compared with the lysates from non-transfected Jurkat T 
cells and Jurkat T cells expressing GFPN-CLEC16A and CLEC16A-GFPC (figure 3.4).  
 
    
Figure 3.4. Expression of GFP-tagged CLEC16A in Jurkat T cells. Jurkat T cells were transfected 
with CLEC16A-GFPC, GFPN-CLEC16A or GFP. Transfected cells were harvested and lysed, and 20 
µg of total proteins were used for the sample with GFP and 150 µg of total proteins were used for the 
other samples (the order of samples are indicated in figure). For detection, anti-GFP and HRP-
conjugated secondary antibody was used. Expected bands are at approximately150 kDa for GFP-
tagged CLEC16A and 27 kDa for GFP alone, bands of interest are marked by asterisks (*). An 
unidentified band in the lane with GFPN-CLEC16A is marked by plus sign (+). 
αGFP	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Both CLEC16A-constructs with GFP-tag were expressed at the expected size (150 kDa). The 
expected band for GFP (slightly above 25 kDa) can be seen for the positive control. In 
addition, an extra band was seen for GFPN-CLEC16A (marked by +), where the protein size 
seemed to correspond to the size of GFP alone or to a protein migrating slightly slower. It 
could also be seen that GFPN-CLEC16A were highly expressed compared to the CLEC16A-




Figure 3.5. Flow cytometry measurement of CLEC16A-GFPC and GFPN-CLEC16A expression 
in transfected Jurkat T cells. Flow cytometry measurements of the expression of (A) CLEC16A-
GFPC and (B) GFPN-CLEC16A. In addition, GFP in pEGFP-N3 (used as measurement for 
transfection efficiency) is shown for each experiment. Data shown are from single, living cells gated 
as described in section 2.2.4. Number in upper right corner of each plot corresponds to the percentage 
of GFP positive cells. Pulsed cells were used as a negative control. 
 
In contrast to the Western blot analyses, flow cytometry measurements were showing almost 
the same expression levels for GFPN-CLEC16A and CLEC16A-GFPC. However, the 
transfection efficiency (see measurements for GFP in figure 3.5) was higher for GFPN-
CLEC16A, but not high enough to explain the difference obtained by Western blot analysis. 
Other flow measurements (figure 3.14) have shown slightly higher expression for N-
terminally GFP-tagged CLEC16A. 
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Expression	  of	  CLEC16A-­‐MYC-­‐DDK	  
Other lab members had earlier determined the optimal amount of CLEC16A-MYC-DDK to 
be transfected into Jurkat T cells for optimal expression, i.e. 3 µg in the transfection and cells 
were harvested 48 hours after transfection.  
 
To confirm the expression of CLEC16A-MYC-DDK in Jurkat T cells, the cells were 
transfected with either the empty plasmid (pCMV6-empty) or pCMV6-CLEC16A-MYC-
DDK (further called CLEC16A-MYC-DDK in this thesis). The expression of CLEC16A-
MYC-DDK was analysed with Western blotting, using an antibody against the DDK-tag, 
where the pCMV6-empty was used as a negative control (figure 3.6). The membrane was 
reprobed with anti-Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) to control the 




Figure 3.6. Expression of CLEC16A-MYC-DDK. Jurkat T cells were transfected with CLEC16A-
MYC-DDK or pCMV6-empty. Transfected cells were harvested and lysed. 80 µg of total protein 
lysate were applied (the order of samples as indicated in figure). The membrane was probed with 
antibody against DDK-tag and HRP-conjugated secondary antibody, and stripped and reprobed with 
antibody against GAPDH and HRP-conjugated secondary antibody. The expected bands were at 125 
kDa for CLEC16A-MYC-DDK and 35 kDa for GAPDH. 
 
The expected size of CLEC16A-MYC-DDK (125 kDa) was confirmed (upper part of figure 
3.6), this band was not present in the lysate from pCMV6-empty transfected cells despite that 
equal amounts of protein were loaded on gel (lower part of figure 3.6).  
α-DDK 
α-GAPDH 
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3.2 Localization	  of	  CLEC16A	  
Earlier published data have shown different subcellular localizations of CLEC16A in 
different cell types. CLEC16A has been shown to localize at lysosomes in pancreatic β cells 
(Min β cells) (68) and at ER in a human erythroleukemia cell-line (K562 cells) (69). 
Publications for the CLEC16A ortholouge in Drosophila, Ema, have shown localization for 
Ema at Golgi in fat body cells of Drosophila Melanogaster (70) and at late endosomes in 
garland cells of Drosophila Melanogaster (71) (more details in section1.3.3). This thesis 
investigated the localization of CLEC16A in Jurkat T cells. The subcellular localization has 
not been studied earlier in immune cells.  
 
3.2.1 CLEC16A-­‐DDK	  and	  CLEC16A-­‐GFPC	  
One limitation using overexpression of tagged proteins for subcellular localization studies is 
that the tag can affect the protein so that it does not behave as endogenous proteins. To get an 
indication if the GFP tag was interfering with the localization of CLEC16A, CLEC16A-GFPC 
was co-transfected with CLEC16A-MYC-DDK. Since the DDK tag is considerable smaller, 
we expected that tag to give less distraction regarding the localization of CLEC16A than the 
GFP tag. The cells were harvested and immunostained with anti-DDK before the cells were 




Figure 3.7. CLEC16A-GFPC was partially co-localized with CLEC16A-MYC-DDK. Jurkat T 
cells transfected with CLEC16A-GFPC and CLEC16A-MYC-DDK were stained with Hoechst, 
mounted on poly-L-lysine coated glass-slides, fixed and permeabilized before immunostaining with 
anti-DDK and Alexa555-conjugated secondary antibody. The cells were analysed by confocal 
microscopy. Indicated area is enlarged with arrowheads pointing at strong signals in the same place 
on all images. In the merged image, Hoechst is indicated in blue, CLEC16A-GFPC in green, 
CLEC16A-MYC-DDK in red and co-localized parts in yellow. One representative cell is shown from 
3 experiments. Scale bars are 10 µm. 
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The confocal images (figure 3.7) showed partly co-localization between the C-terminally 
tagged-CLEC16A proteins.  
 
3.2.2 CLEC16A-­‐DDK	  and	  GFPN-­‐CLEC16A	   	  
To further examine the subcellular localization of CLEC16A, an N-terminally GFP-tagged 
CLEC16A was created (described in section 3.1). Since CLEC16A-GFPC and CLEC16A-
MYC-DDK not were completely co-localized, the localization of GFPN-CLEC16A was 
further compared with CLEC16A-MYC-DDK. Jurkat T cells were transfected with plasmids 
encoding these proteins and the cells were harvested and immunostained with anti-DDK 




Figure 3.8. GFPN-CLEC16A was co-localized with CLEC16A-MYC-DDK. Jurkat T cells were 
transfected with GFPN-CLEC16A and CLEC16A-MYC-DDK. The cells were stained with Hoechst, 
mounted on poly-L-lysine coated glass-slides, fixed and permeabilized before immunostaining with 
anti-DDK and Alexa555-conjugated secondary antibody. The cells were analysed by confocal 
microscopy. Indicated area is enlarged with arrowheads pointing at strong signals in the same place 
on all images. In the merged image, Hoechst is indicated in blue, GFPN-CLEC16A in green, 
CLEC16A-MYC-DDK in red, and co-localized parts in yellow. One representative cell is shown from 
one experiment. Scale bars are 10 µm. 
 
In contrast to CLEC16A-GFPC, the confocal microscopy analysis showed co-localization 
between GFPN-CLEC16A and CLEC16A-MYC-DDK. This indicates that both of tagged 
CLEC16A proteins were in the same localization.  
 
When comparing the pattern left by the GFP signals in GFPN-CLEC16A and CLEC16A-
GFPC, some differences were detected, but both have distinct signals in small puncta (see 
arrowheads for the GFP signal in figure 3.7 and 3.8). These punctas were of interest to 
identify, and since both CLEC16A and Ema earlier have been shown to localize in 
endosomes (68, 71), the intracellular markers chosen for the identification, represents the 
endosomal pathway (for details about endosomal pathway, see section 1.2.2). The main 
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difference detected in the two GFP signals was a diffuse signal throughout the cell that was 
observed in GFPN-CLEC16A, but not in CLEC16A-GFPC. 
 
3.2.3 Endogenous	  CLEC16A	  staining	  
Since the localizations of the tagged CLEC16A proteins were different, endogenous staining 
was tested to find the subcellular localization.	  	  	  
To get the most accurate results, endogenous staining of the protein of interest is preferred 
compared to transient overexpressing of the protein by transfection. The lack of specific 
antibodies is the biggest challenge for endogenous staining. To test the specificity of two 
antibodies against CLEC16A, Jurkat T cells transfected with CLEC16A-GFPC, control 
siRNA or CLEC16A-specifc siRNA, were immunostained with anti-CLEC16A from 
Millipore (Figure 3.9) and anti-CLEC16A from abcam (data not shown). The purpose of 
transfecting the cells with CLEC16A-GFPC prior to immunostaining was to examine whether 
GFP and anti-CLEC16A signals were co-localized (figure 3.9 A). The cells transfected with 
control siRNA (figure 3.9 B), or CLEC16A-specific siRNA (figure 3.9 C) were 
immunostained to examine if the anti-CLEC16A signals were reduced in CLEC16A-siRNA 
treated cells compared to control cells. 
 
There was co-localization of the GFP signal and the CLEC16A-antibody signal (figure 3.9 
A), indicating that the CLEC16A antibody binds to overexpressed CLEC16A. However, for 
the CLEC16A-siRNA and control-siRNA treated cells (figure 3.9 B and C) there was a 
reduction in CLEC16A-antibody signals for CLEC16A-siRNA treated cells in the first 
experiment, but in the second experiment there was a reduction for the signal in control-
siRNA cells. In the third experiment no difference could be seen. This indicates that the anti-
CLEC16A signals were unspecific binding or background from the high voltage settings 
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Figure 3.9. CLEC16A antibody does not bind specifically to endogenous CLEC16A. Jurkat T 
cells transfected with (A) CLEC16A-GFPC were stained with Hoechst, mounted on poly-L-lysine 
coated glass-slides, fixed and permeabilized before immunostaining with anti-CLEC16A (Millipore) 
and Alexa647-conjugated secondary antibody. Indicated area is enlarged with arrowheads pointing at 
strong signals in the same place on all images. In the merged image, Hoechst is indicated in blue, 
CLEC16A-GFPC in green, CLEC16A-antibody (Millipore) signals in red and co-localized parts in 
yellow. One representative cell is shown from one experiment. Jurkat T cells transfected with (B) 
control siRNA and (C) CLEC16A-specific siRNA were immunostained as described for (A). A 
representative section from three independent experiments is shown. In the merged image Hoechst is 
indicated in blue and CLEC16A-antibody (Millipore) signals in red. All scale bars are 10 µm. 
 
To exclude that the varying result from the staining with the CLEC16A-antibody was due to 
lack of proper CLEC16A-knockdown after transfection with CLEC16A-specific siRNA, the 
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knocked down was confirmed. The transfected cells were harvested and lysed for further 
analysis on Western blot with CLEC16A-antibody (figure 3.10). 
 
    
 
Figure 3.10. CLEC16A was knocked down at protein level in Jurkat T cells transfected with 
CLEC16A-specific siRNA. Jurkat T cells transfected with CLEC16A-MYC-DDK, CLEC16A-
siRNA, or control-siRNA were harvested and lysed. Protein concentrations were measured prior to 
Western blot analysis, where 120 µg of total proteins were used. (A) The membrane was probed with 
anti-CLEC16A (millipore) and HRP-conjugated secondary antibody and (B) reprobed with anti-
GAPDH and HRP-conjugated secondary antibody. The band was expected at 125 kDa, and is marked 
by asterisks (*). 
 
Western blot analysis confirmed knockdown of CLEC16A expression at the protein level 
after transfection with CLEC16A-specific siRNA compared with cells transfected with 
control siRNA (see upper part of figure 3.10). Even though the bands were weak, the results 
fit with the procedure established in the lab, which confirms knockdown of CLEC16A in 
Jurkat T cells at both protein and messenger RNA (mRNA) level 48 hours after transfection. 
Additionally, the loading control indicated more total proteins in the CLEC16A-siRNA 
samples compared to control-siRNA (see lower part of figure 3.10) 
 
3.2.4 Cellular	  Fractionation	  
Since endogenous staining not could be performed, cellular fractionations were executed on 
Jurkat T cells transfected with the different tagged CLEC16A proteins and on untreated 
Jurkat T cells. It was performed to examine if the GFP/DDK-tagged CLEC16A proteins were 
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In the fractionation kit (Compartmental Protein Extraction kit, Millipore) four fractions were 
collected, i.e. cytosolic-, nuclear-, membrane- and cytoskeleton fraction. Untreated Jurkat T 
cells were used to optimize the procedure. The purity was examined in each fraction with 
antibodies against housekeeping proteins with specific localization (cytosol: GAPDH, 
nuclear: lamin B1, membrane: epidermal growth factor receptor (EGFR), cytoskeleton: 
vimentin). When performing the protocol according to the manufacturers’ recommendations, 
the nuclear proteins were detected in all fractions when being analysed by Western blot with 
anti-lamin B1 (nuclear protein). In addition, the membrane fraction seemed to have a very 
low amount of proteins on Bradford assay. The antibody that was used to detect membrane 
proteins (anti-EGFR) showed a signal in the positive control, but not in any of the other 
fractions (data not shown).  
 
The method was optimized with focus on the nuclear fraction. The diameter of the needle 
used to free the nucleus from the rest of the cell was reduced, and the step where the cells 
were incubated with nuclear lysis buffer was repeated with double amount of nuclear lysis 




Figure 3.11. Nuclear proteins (lamin B1) were detected in all fractions. Expression of a nuclear 
protein (lamin B1) in extracted fractions from Jurkat T cells after optimizing the method for cellular 
fractionation, described above. The protein concentrations were measured, and 1,9 µg total proteins 
were used in Western blot analysis (the fractions are indicated in figure). Lamin B1 was detected with 
anti-lamin B1 and HRP-conjugated secondary antibody. 
 
The nuclear proteins were still found in all fractions after optimization, and since the confocal 
microscopy images (see figure 3.7, 3.8) indicated that CLEC16A (or at least GFP/DDK-
tagged CLEC16A) was not likely to be in the nucleus, we decided to discard this fraction. 
Furthermore, optimization for the membrane fraction was not performed, due to time limit. 
 
α- Lamin B1 
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Fractionations were performed in Jurkat T cells transfected with plasmids expressing GFPN-
CLEC16A, CLEC16A-GFPC and CLEC16A-MYC-DDK. In addition, untreated Jurkat T 
cells were included enabling us to study the localization of endogenously expressed 
CLEC16A. Prior to fractionation, flow cytometry was performed to confirm protein 
expression of GFP-tagged CLEC16A proteins. Also, the efficiency of the transfection was 
measured (figure 3.14).  
 
The concentrations of the proteins in the extracted fractions were measured by Bradford 
assay. Some of the samples had values that were too low to be determined. Previously 
(during optimization) we have applied the same amount of proteins on the SDS 
polyacrylamide gel for the analyses, but since the concentration for some fractions was 
undetermined, lysate from the same cell count was used instead. For each fraction, duplicates 
were applied on the gel, where one of the duplicates was used to examine the purity of the 
fractions with antibodies against housekeeping proteins (figure 3.12) and the other was used 




Figure 3.12. Analyses of cell fraction purity. Cellular fractions from 0,4 million cells were analysed 
on Western blot. Anti-GAPDH (and HRP-conjugated secondary antibody) and anti-vimentin (and 
HRP-conjugated secondary antibody) were used as subcellular markers for cytosol and cytoskeleton 
fractions, respectively. The expected band for GAPDH and vimentin are 35 kDa and 54 kDa. One 
representative membrane out of four is shown. 
 
Unfortunately, when the purity of the fractions was examined, we could not detect the 
membrane proteins (used anti-EGFR) in any of the fractions except for in the total lysate 
(data not shown). However, vimentin was observed only in cytosolic fraction, as expected, 
α-vimentin 
α-GAPDH 
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and GAPDH was observed mostly in cytosolic fraction, with small amounts expressed in the 
membrane and the cytoskeleton fraction (figure 3.12). 
 
When investigating in which fraction the GFP/DDK-tagged CLEC16A were located, only 
GFPN-CLEC16A and CLEC16A-MYC-DDK were detected on Western blot at the expected 





Figure 3.13. CLEC16A-MYC-DDK and GFPN-CLEC16A were detected in the cytoskeleton 
fraction. The localization of GFPN-CLEC16A and CLEC16A-MYC-DDK after performing 
subcellular fractionation on transfected Jurkat T cells. Fractions indicated corresponding to 0,4 
million cells analysed on Western blot. (A) anti-GFP (and HRP-conjugated secondary antibody) or 
(B) anti-DDK (and HRP-conjugated secondary antibody) were used to detect GFPN-CLEC16A and 
CLEC16A-MYC-DDK, respectively. The expected band for GFPN-CLEC16A and CLEC16A-MYC-
DDK are 150 kDa and 130 kDa. Bands of interest are indicated by asterisks (*).  
 
The flow cytometry measurements performed prior to the cellular fractionations showed 
expression of CLEC16A-GFPC (figure 3.14). However, it showed higher expression of GFPN-
CLEC16A than CLEC16A-GFPC, despite that the transfection efficiency was higher for the 
latter. CLEC16A-GFPC could not be detected when the fractions were analysed on Western 
blot. It has earlier shown to be difficult to detect in Western blot analysis with GFP-antibody, 
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Figure 3.14. Expression of GFPN-CLEC16A and CLEC16A-GFPC prior to cellular fractionation 
of Jurkat T cells transfected with GFP-tagged CLEC16A plasmids. Flow cytometry 
measurements of the expression of (A) GFPN-CLEC16A and (B) CLEC16A-GFPC. In addition, GFP 
in pEGFP-N3 (used as measurement for transfection efficiency) is shown for each experiment. Data 
shown are from single, living cells gated as described in section 2.2.4. Number in upper right corner 
of each plot corresponds to the percentage of GFP positive cells. Pulsed cells were used as a negative 
control. 
 
To summarize the cellular fractionation: Cytoskeleton proteins were only located in the 
cytoskeleton fraction and cytosolic proteins were mostly located in the cytosolic fraction, but 
with small amounts in both the membrane fraction and the cytoskeleton fraction (figure 3.12). 
Membrane proteins could not be detected. GFPN-CLEC16A and CLEC16A-MYC-DDK were 
localized in the cytoskeleton fraction (figure 3.13), which can mean that they were localized 
in either the membrane fraction or the cytoskeleton fraction. Endogenous CLEC16A and 
CLEC16A-GFPC could not be detected.  
 
3.2.5 The	  intracellular	  localization	  of	  the	  tagged	  CLEC16A	  proteins	  
The subcellular localization was further examined with the tagged CLEC16A-proteins. We 
analysed whether DDK/GFP-tagged CLEC16A was co-localized with the following 
organelles (with indicated organelle marker); early endosomes (Rab5), late endosomes 
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(Rab7), recycling endosomes (Rab4a), trans-golgi network (TGN46) and lysosomes 
(LAMP1), in confocal microscopy. Rab molecules were visualized by transfection of 
plasmids expressing Rab molecule fused with a fluorescent molecule. Rab5 and Rab4a were 
fused with mCherry and Rab7 was fused with GFP. To detect lysosomes and trans-golgi 
network, cells were stained with antibodies for LAMP1 and TGN46, respectively.  
 
Intracellular	  localization	  for	  CLEC16A-­‐MYC-­‐DDK	  
Jurkat T cells transfected with CLEC16A-MYC-DDK were either co-transfected with the 
different Rab-constructs (Rab4a-mCherry, Rab5-mCherry, Rab7-GFP) and immunostained 
with anti-DDK, or immunostained with anti-DDK and anti-TGN46 or anti-DDK and anti-
LAMP1. The different samples were analysed by confocal microscopy (see figure 3.15) 
 
CLEC16A-MYC-DDK was partially co-localized with recycling-(Rab4a) endosomes (middle 
row, Figure 3.15). Additionally it was partially co-localized with early-(Rab5) endosomes in 
the perinuclear area (row number two, figure 3.15). No co-localization was observed with 
Rab7, TGN46 or LAMP1.  
 
	   59	  
 
Figure 3.15. CLEC16A-MYC-DDK was	  partially co-localized with Rab4a and Rab5. Jurkat T 
cells transfected with CLEC16A-MYC-DDK and the Rab-construct indicated in figure. The cells 
were stained with Hoechst, mounted on poly-L-lysine coated glass slides, fixed and permeabilized 
before immunostaining with anti-DDK and Alexa647-conjugated secondary antibody or Alexa555- 
conjugated secondary antibody (only for Rab7-GFP). Jurkat T cells overexpressing only CLEC16A-
MYC-DDK were treated as above, but immunostained with anti-DDK and Alexa555-conjugated 
secondary antibody in addition to anti-TGN46 or anti-LAMP1 and Alexa647-conjugated secondary 
antibody. The samples were analysed by confocal microscopy. Indicated areas are enlarged with 
arrowheads pointing at strong signals at the same place in all images. In the merged image; Hoechst is 
indicated in blue, CLEC16A-MYC-DDK in green, the organelle marker indicated in red and co-
localized parts in yellow. Scale bars are 10 µm. One representative cell is shown from one experiment 
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for the cellular markers TGN46 and Rab7, two independent experiments for the cellular markers Rab5 
and LAMP1 and three independent experiments for the cellular marker Rab4a.  
 
Intracellular	  localization	  of	  CLEC16A-­‐GFPC	  
Jurkat T cells transfected with CLEC16A-GFPC were either co-transfected with Rab-
constructs (Rab4a and Rab5) or immunostained with anti-TGN46 or anti-LAMP1. The 
different samples were analysed on confocal microscopy (see figure 3.16). The late 




Figure 3.16. CLEC16A-GFPC showed co-localization with Rab4a and partial co-localization 
with Rab5. Jurkat T cells transfected with CLEC16A-GFPC and the Rab-constructs indicated in the 
figure, were stained with Hoechst, mounted on poly-L-lysine coated glass slides and fixed. Jurkat T 
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cells expressing only CLEC16A-GFPC were treated as above but also permeabilized and 
immunostained with anti-TGN46 or anti-LAMP1 and Alexa647-conjugated secondary antibody. The 
samples were analysed by confocal microscopy. Indicated areas are enlarged with arrowheads 
pointing at the strong signals at the same place in all the images. In the merged image; Hoechst is 
indicated in blue, CLEC16A-GFPC in green, the organelle marker is indicated in red and co-localized 
parts in yellow. Scale bars are10 µm. One representative cell is shown from one experiment for the 
cellular marker TGN46, two independent experiments for the cellular markers LAMP1 and Rab5, and 
three experiments with the cellular marker Rab4a. 
  
Based on the confocal analysis of CLEC16A-GFPC with the different organelle markers, 
CLEC16A-GFPC showed co-localization with Rab4a-endosomes (row three, figure 3.16). In 
addition, CLEC16A-GFPC seemed, like CLEC16A-MYC-DDK, to be partially co-localized 
with Rab5-endosomes in the perinucleuar area (row two, figure 3.16). No co-localization 
with TGN46 or LAMP1 was obtained. 
 
Intracellular	  localization	  for	  GFPN-­‐CLEC16A	  
Jurkat T cells transfected with GFPN-CLEC16A were either co-transfected with Rab-
constructs (Rab4a and Rab5) or immunostained with anti-TGN46 or anti-LAMP1. The 
different samples were analysed by confocal microscopy (figure 3.17). As for CLEC16A-
GFPC, the late endosomal marker Rab7 could not be examined since it is fused with GFP. 
 
Based on the confocal analyses for GFPN-CLEC16A with the different organelle markers, 
GFPN-CLEC16A was partially co-localized in Rab4a-positive endosomes (row three, figure 
3.17). No co-localization was obtained with the markers Rab5, TGN46 or LAMP1. 
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Figure 3.17. GFPN-CLEC16A showed partly co-localization with Rab4a. Jurkat T cells were co-
transfected with GFPN-CLEC16A and the Rab-constructs indicated in the figure. The cells were 
stained with Hoechst, mounted on poly-L-lysine coated glass slides and fixed. Jurkat T cells 
transfected with only GFPN-CLEC16A were treated as above, but also permeabilized and 
immunostained with anti-TGN46 or anti-LAMP1 and Alexa647-conjugated secondary antibody. The 
samples were analysed by confocal microscopy. Indicated areas are enlarged with arrowheads 
pointing at strong signals at the same place in all the images. In the merged image; Hoechst is 
indicated in blue, GFPN-CLEC16A in green, the organelle marker is indicated in red and co-localized 
parts in yellow. Scale bars are 10 µm. One representative cell is shown from one experiment. 
  
 
To summarize; CLEC16A-GFPC was located in Rab4a-positive endosomes, meanwhile 
CLEC16A-MYC-DDK and GFPN-CLEC16A were partially co-localized with the marker 
Rab4a. Additionally, CLEC16A-GFPC as well as CLEC16A-MYC-DDK showed partially 
co-localization with the marker Rab5. 
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3.3 Distribution	  of	  endosomes	  	  
To investigate if CLEC16A has an effect on the distribution of endosomes in Jurkat T cells, 
cells were transfected with either CLEC16A-MYC-DDK or CLEC16A-siRNA and the 
corresponding controls, pCMV6-empty or control siRNA respectively. The markers that I 
managed to analyse to complete this thesis were the Rab4a (recycling endosomes), Rab5 
(early endosomes) and LAMP1 (lysosomes). The samples were analysed by confocal 
microscopy and in parallel with Image Stream analyses (done by PhD student Ingvild Sørum 
Leikfoss). Confocal microscopy analyses generate high-resolution images, which will give a 
more detailed view of the cells compared to Image Stream. However, Image Stream is a 
powerful tool combining quantitative image analysis with flow cytometry that can verify and 
quantify statistically the results observed by confocal microscopy. 
 
CLEC16A-MYC-DDK, CLEC16A-specific siRNA and controls, were either co-transfected 
with the Rab-construct or immunostained with anti-LAMP1. In all experiments, the 
transfection efficiency was measured by flow cytometry on Jurkat T cells transfected with 
pEGFP-N3. The knockdown and overexpression of CLEC16A was confirmed by Western 
blot or real-time quantitative PCR (qPCR). These verifications were done by PhD student 
Ingvild Sørum Leikfoss, whereas the sample preparation on glass slides for confocal 
microscopy was done by me.  
 
3.3.1 Distribution	  of	  Rab4a-­‐endosomes	  
The possible effect of CLEC16A on the distribution of Rab4a was investigated in Jurkat T 
cells. The cells were transfected with either CLEC16A-MYC-DDK or CLEC16A siRNA and 
the corresponding controls.  
 
No obvious differences were detected in the Rab4a-positive endosomal distribution in Jurkat 
T cells overexpressing CLEC16A or in cells where CLEC16A were knocked down compared 
to their respective control (Figure 3.18). The Rab4a-marker used was expressed with a 
mCherry, which gave blurry images lacking clear cell structures, making it difficult to detect 
differences in endosomal distribution. However, the cells seemed to be larger for Jurkat T 
cells overexpressing CLEC16A compared to the other cells (see figure 3.18 B). 
 
	   64	  
Preliminary results from Image Stream shows no obvious differences regarding the Rab4a-
endosomal distribution in knocked down- or overexpressed CLEC16A Jurkat T cells.  
 
 
Figure 3.18. CLEC16A did not seem to affect the distribution of Rab4a-endosomes in Jurkat T 
cells. Jurkat T cells transfected with Rab4a-mCherry and (A) pCMV6-empty, (B) CLEC16A-MYC-
DDK, (C) control siRNA or (D) CLEC16A-siRNA were stained with Hoechst, mounted on poly-L-
lysine coated glass slides and fixed. The samples were analysed by confocal microscopy. In the 
merged image; Hoechst is indicated in blue and Rab4a-mCherry in red. Scale bars are 10 µm. Data 
shows three representative cells from each group from one experiment performed.  
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3.3.2 Distribution	  of	  Rab5-­‐endosomes	  
To investigate the distribution of Rab5 endosomes, Jurkat T cells were transfected with either 
CLEC16A-MYC-DDK or CLEC16A siRNA and the corresponding controls. The samples 
were analysed by confocal microscopy (see figure 3.19). 
 
 
Figure 3.19. CLEC16A knockdown caused an increased number Rab5-endosomes in Jurkat T 
cells, which were more scattered throughout the interior of the cell. Jurkat T cells transfected with 
Rab5-mCherry and (A) pCMV6-empty, (B) CLEC16A-MYC-DDK, (C) control siRNA or (D) 
CLEC16A-siRNA, were stained with Hoechst, mounted on poly-L-lysine coated glass slides and 
fixed. The samples were analysed by confocal microscopy. In the merged image; Hoechst is indicated 
in blue and Rab5-mCherry in red. Scale bars are 10 µm. Three representative cells from each group 
from one experiment performed.  
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Jurkat T cells overexpressing CLEC16A resulted in evenly distributed Rab5-positive 
endosomes in close proximity to the plasma membrane (figure 3.19 B). For the corresponding 
control (see figure 3.19 A), the Rab5-positive endosomes were located in one intense spot in 
perinuclear area or distributed similar to the overexpressed cells. For the cells where 
CLEC16A was knocked down (see figure 3.19 D), there seemed to be an increased number of 
Rab5-positive endosomes compared to the corresponding control (see figure 3.19 C). The 
Rab5-positive endosomes seemed to be located in a larger area in the CLEC16A knocked 
down cells compared to the intense spot in the control. The knocked down CLEC16A cells 
also had an over-all weaker mCherry signal. Additionally, Jurkat T cells with CLEC16A 
overexpression were larger in size (same as for Rab4a, section 3.3.1) and less spherical 
compared to the other groups. 
 
Image Stream analysis has not yet detected any major differences regarding the distribution 
of Rab5-positive endosomes in overexpression or knockdown of CLEC16A compared to 
controls (in Jurkat T cells). The Image stream analysis performed has been focusing on the 
distribution of the most intense mCherry signal in the cells relative to the plasma membrane 
and compared it between the different cell populations.  
 
3.3.3 Distribution	  of	  LAMP1-­‐endosomes	  
In this experiment, the cells transfected with CLEC16A-MYC-DDK was not included due to 
infection of the cell culture. Therefore it was only possible to analyse LAMP1 distribution in 
CLEC16A-specific siRNA transfected Jurkat T cells and corresponding control cells. 
Transfected Jurkat T cells were immunostained with anti-LAMP1 and analysed by confocal 
microscopy (figure 3.20).  
 
Decreased amount of CLEC16A did not seem to influence the distribution of LAMP1-
positive lysosomes. However, there were some indications that LAMP1 expression was 
higher in cells with CLEC16A knocked down.  
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Figure 3.20. CLEC16A did not affect the distribution of LAMP1 lysosomes in Jurkat T cells. 
Jurkat T cells transfected with (A) control-siRNA or (B) CLEC16A-siRNA, were stained with 
Hoechst and mounted on poly-L-lysine coated glass slides, fixed and permeabilized before 
immunostaining with anti-LAMP1 and Alexa647-conjugated antibody. The samples were analysed by 
confocal microscopy. In the merged image; Hoechst is indicated in blue and LAMP1 in red. Data 
shows two representative sections from each sample, from one experiment performed. Scale bars are 
10 µm.  
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4 Discussion	  
This thesis has two main aims (described in section 1.5) and the discussion will focus on the 
results regarding them. The background for this thesis is that the CLEC16A gene has been 
identified to associate with MS and by finding the subcellular localization of the protein 
encoded by this MS-associated gene, it will shed light on potential functions.  
 
4.1 Comparison	  of	  the	  differently	  tagged	  CLEC16A	  proteins	  
Proteins are often dependent on sorting signals or specific interactions with other proteins for 
correct localization in the cells and tissues. By adding a tag to a protein the sorting processes 
can be disrupted and wrong localization may be obtained.  
 
4.1.1 Endogenous	  staining	  
Since protein tags might affect the subcellular localization of proteins, the most accurate way 
to find the localization is by analysing the endogenous protein. When examining in confocal 
microscopy with immunostaining, the challenge is to find a working antibody for this 
purpose. The antibody needs to be both specific and sensitive. In the test we performed 
(figure 3.9) two antibodies were tested (Millipore, abcam). One of the antibodies (Millipore) 
did bind to CLEC16A when GFP-tagged CLEC16A was overexpressed in Jurkat T cells, as 
immunostaining signals from the CLEC16A antibody co-localized with the GFP signal 
(figure 3.9 A). However, the antibody was probably not sensitive enough to bind endogenous 
CLEC16A in Jurkat T cells, since no reduction could be detected when comparing staining in 
cells where CLEC16A was knocked down with control cells (see figure 3.9 B and C). The 
signals detected for the antibody are probably noise from high laser intensity and high 
voltage settings.  
 
4.1.2 Comparison	  of	  localization	  of	  GFP	  and	  DDK-­‐tagged	  CLEC16A	  
For the purpose of finding the localization of CLEC16A, N- and C-terminally GFP-tagged 
CLEC16A plasmids were created (section 3.1). The localization of both GFP-tagged 
CLEC16A proteins was compared to the localization of a C-terminally MYC-DDK-tagged 
CLEC16A (available in the lab). Since the MYC-DDK-tag is considerably smaller than the 
GFP tag, we would think that CLEC16A with the MYC-DDK-tag would localize more 
similar to endogenous CLEC16A compared to CLEC16A with a GFP-tag. The C-terminally 
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GFP-tagged CLEC16A did show partial co-localization with the MYC-DDK-tagged 
CLEC16A (figure 3.7). However, higher degree of co-localization was obtained between 
CLEC16A-MYC-DDK and N-terminally GFP-tagged CLEC16A (figure 3.8). The C-terminal 
side of CLEC16A is predicted to be unstructured (section 1.3.2), which means that it 
probably can move quite freely and might be important for interactions with other proteins 
that can influence its subcellular localization. These interactions can be disturbed when 
adding a large GFP tag. Since endogenous CLEC16A could not be detected in the fractions 
obtained from cellular fractionation, we could not compare the localization with the 
localizations from the tagged CLEC16A. However, since CLEC16A-MYC-DDK and GFPN-
CLEC16A is co-localized, it is more likely that they show the right localization for 
endogenous CLEC16A then CLEC16A-GFPC. 
 
When the expression of the N-terminally GFP-tagged CLEC16A in Jurkat T cells was 
investigated, the proteins were detected on Western blot with an antibody against GFP. In 
addition to the expected signal, there was one more protein detected by the GFP-antibody 
(figure 3.4). The signal corresponds to a protein slightly larger than GFP. This has been 
detected twice on Western blot, but the protein-lysate was from the same cells. The extra 
band can be an artefact from any of the treatments (transfection, making whole cell lysates or 
Western blot) prior to detection, and it is too early to conclude if this occurs routinely when 
overexpressing GFPN-CLEC16A in Jurkat T cells. However, we must take into consideration 
that the GFP signal obtained in confocal microscopy and Image Stream for N-terminally 
GFP-tagged CLEC16A can be obtained from any of these two proteins. It can explain why a 
diffuse signal throughout the cell is detected when GFPN-CLEC16A is expressed. If the band 
detected on Western blot is a protein obtained due to cleavage of the GFPN-CLEC16A 
protein, the cause of the cleavage can be that the link created between GFP and CLEC16A is 
instable and may be processed by proteases, or if the cleavage is in the CLEC16A protein it 
could be a signal sequence, which is cleaved in the process. To further understand this, more 
studies are needed.  
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4.1 Do	  CLEC16A	  have	  different	  localization	  in	  different	  
cells?	  
During the work on this thesis, two new studies have been published regarding the function 
of CLEC16A (68, 69). In those papers, CLEC16A shows various localizations in different 
cell-types, indicating that CLEC16A localization is tissue-dependent. It can also be 
dependent on which isoform of CLEC16A that has been studied, and that the various 
CLEC16A-isoforms (figure 1.7) are localized differently. Earlier work has shown that 
CLEC16A-isoform 1 (24 exons) is localized in ER in human erythroleukemia cell-line (K562 
cells) (69), CLEC16A-isoform 2 (21 exons) is localized in lysosome/late endosome in 
pancreatic β-cells (Min6 β) (68) and Ema (CLEC16A ortholouge in Drosophila 
melanogaster) has been shown to localize in late endosomes in Drosophila melanogaster 
garland cells (71) and in Golgi in Drosophila melanogaster fat body cells (70). Here we 
identify CLEC16A-isoform 1 to be partially localized in Rab4a recycling endosomes in 
Jurkat T cells (figure 3.15, 3.16, 3.17). A lower degree of co-localization is also observed 
between CLEC16A and Rab5 (early endosome) however, no co-localization with Rab7 (late 
endosome), LAMP1 (lysosome) or TGN46 (Golgi) was observed in Jurkat T cells.  
 
Furthermore, earlier studies have shown that CLEC16A is a membrane-associated protein, 
since it was detected in cellular fractions from both cytosol and membrane (68). When we 
performed cellular fractionation, we could exclude presence of CLEC16A in the cytosol in 
Jurkat T cells (figure 3.13), however, due to technical problems we were not able to identify 
whether CLEC16A was present in the membrane fraction also in T cells. 
 
This together indicates that CLEC16A can be differently localized in various cells, but it 
cannot be excluded that the differences are seen due to overexpression of the proteins, since 
endogenous staining has not yet been performed in any of the studies. In addition, different 
CLEC16A isoforms could have different localizations within the cells. 
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4.2 Do	  CLEC16A	  have	  a	  role	  in	  endosomal	  trafficking?	  
Earlier studies have shown that CLEC16A has a role in endosomal trafficking and autophagy 
(68, 70, 71). We find that CLEC16A is partially localized in Rab4a recycling endosomes in 
Jurkat T cells, and when CLEC16A is knocked down the cells have characteristics indicating 
endosomal trafficking defects, as observed accumulations of early endosomes and lysosomes 
(figure 3.19 and 3.20). 
 
4.2.1 CLEC16A	  is	  partially	  localized	  in	  Rab4a-­‐recycling	  endosomes	  	  
To reveal the subcellular localization of CLEC16A, all three DDK/GFP-tagged CLEC16A 
proteins were analysed with intracellular markers in confocal microscopy (see figure 3.15, 
3.16, 3.17). They all are partially co-localized with Rab4a-recycling endosome, CLEC16A-
GFPC more than the two other CLEC16A tagged proteins (figure 3.15, 3.16, 3.17). The 
Rab4a-positive recycling endosomes are thought to be responsible for rapid recycling 
between early endosomes (Rab5-positive) and the plasma membrane (11). Since CLEC16A 
is not detected on the plasma membrane, it is more likely that CLEC16A is resident in those 
endosomes than transported by them. The proteins that utilize this pathway are often cell 
surface receptors, like the transferrin receptor and TCR (14), but also tyrosine kinases, 
integrins (13) among others.  
 
4.2.2 Do	  CLEC16A	  have	  a	  role	  in	  rapid	  recycling?	  
Previous studies have shown that Rab4-endosomal recycling is decreased in Rab4 mutant 
HeLa cells, leading to accumulation of early endosomes (Rab5-positive) in the perinuclear 
area (75). As in the Rab4 mutant cells, we observed an increased amount of Rab5 endosomes 
in CLEC16A siRNA transfected cells (see figure 3.19 D). This may indicate that CLEC16A 
has a role in the rapid recycling between Rab5 endosomes and the plasma membrane. A route 
that receptors like TCR is known to use (14) (described further in section 1.1.2).  
 
An earlier CLEC16A study has shown that when CLEC16A is knocked down in B cells, 
there was no effect on the B cell´s ability to activate T cells, indicating that the MHC class II 
presentation was not dependent of CLEC16A in B cells (69). In contrast, a lower expression 
of HLA-II presented on the plasma membrane in monocyte derived dendritic cells has been 
observed when CLEC16A is knocked down compared to control (personal communication 
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Luijn) (more details in section 1.4.3). It remains to be studied whether the decreased HLA-II 
presentation in dendritic cells is affecting the T cell activation. In addition it remains to be 
analysed, whether the effect of CLEC16A knocked down in T cells has the same effect on 
TCR expression on the cell surface on T cells, as HLA-II in dendritic cells. A PhD student in 
our lab has analysed expression of T cell activation markers in Jurkat T cells, however, 
preliminary data does not indicate a change in their cell surface expression when CLEC16A 
is knocked down. The activation is performed with ionomycin and PMA, which do not 
require interactions with the TCR. There may be an effect on cell surface expression of 
activation markers if the T cell is activated through the TCR instead. 
 
4.2.3 Do	  CLEC16A	  knockdown	  cause	  failure	  in	  endolysosomal	  trafficking?	  	  
In addition to the accumulated Rab5-endosomes (see figure 3.19 D) described above, there 
were indications that LAMP1 lysosomes accumulated in CLEC16A-knocked down cells 
(figure 3.20 B), which could indicate a trafficking problem in the endolysosomal trafficking. 
Ema mutant cells have shown defects in regulating the trafficking of cell membrane 
receptors, as has been observed for the bone morphogenetic protein signalling pathway 
receptors. In Ema mutant cells, the late endosomes can not be converted into degradative 
lysosomes (71). Additionally, for CLEC16A-knock out pancreatic β cells, defects in 
endolysosomal trafficking has been shown to have implications in autophagy, when 
autophagosomes not are able to fuse with lysosomes (68). If the result obtained from this 
thesis regarding the lysosomal accumulation is reproducible, CLEC16A could have a role in 
autophagy in immune cells as well as in pancreatic β cells as shown by (68). 
 
As stated in the result part, preliminary results from Image Stream analyses have not 
identified any major differences in the endosomal distribution of the markers tested. 
However, with the more detailed images obtained by confocal microscopy, the analyses 
should be more specific against the accumulation of small Rab5 endosomes and the LAMP1-
lysosome accumulation, instead of only analysing the distribution of the most intense spots 
during Image Stream analyses. 
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4.3 Methodological	  considerations	  
In this thesis, confocal microscopy has been a central part and Image Stream is going to be 
used to quantify the result seen in confocal microscopy. The considerations about the 
methods used are discussed here.  
 
4.3.1 Overexpression	  of	  proteins	  
In the current study, we are analysing subcellular localization and endosomal distribution of 
proteins that mostly are overexpressed, i.e. for CLEC16A as well as for all markers, except 
LAMP1 and TGN46. By overexpressing proteins, they will not necessarily behave as 
endogenous proteins do and the result is more an indication of how it can be biological 
relevant. The best way for study a protein is when using antibodies, with high specificity and 
sensitivity, to be able to detect the endogenous protein.  
 
4.3.2 Transient	  transfections	  
In this thesis, transient transfections are performed to introduce exogenous DNA/RNA. When 
performing transient transfection, all cells in a population are not being transfected. 
Additionally the transfected cells do express highly variable levels of the exogenous DNA. A 
more accurate way of analysing cells with introduced DNA/RNA, is to create stable cell-
lines. All cells in a population will then contain the DNA of interest and express it, however, 
the levels are still probably higher than the endogenous levels.  
 
4.3.3 Use	  of	  cell	  line	  
The cell model used to investigate CLEC16A in this thesis is the Jurkat TAg T cell line. This 
cell line is established from Jurkat E6.1, which is derived from peripheral blood of a patient 
with T cell leukemia (76) (more detail in section 2.2). Cell lines are very convenient to work 
with since the cells grow rapidly and the same cell batch can be used through several 
passages. However, it has some limitations. Since the cells are affected by cancer, the cells 
are not behaving in the same way, as primary T cells would do. The results need to be 
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4.4 Summary	  of	  findings	  
 
The aims for this thesis were to investigate the subcellular localization for CLEC16A, and to 
evaluate its role in endosomal distribution, both examined in T cells.  
 
The main findings were: 
 
4.4.1 Localization	  of	  CLEC16A:	  
Confocal microscopy shows that CLEC16A is partially co-localized with Rab4a, a marker for 
endosomes that rapidly recycle from early endosomes to the plasma membrane. 
 
4.4.2 The	  role	  of	  CLEC16A	  in	  endosome	  distribution:	  
Confocal microscopy data shows accumulation of early endosomes and lysosomes in Jurkat 
T cells where CLEC16A has been knocked down, indicating a defect in endosomal 
trafficking.  
 
The early endosomal accumulation observed in CLEC16A knocked down T cells together 
with the CLEC16A localization in recycling endosomes, indicate that CLEC16A have a role 
in recycling from early endosomes. 
 
In addition, the lysosomal accumulation indicates that CLEC16A have a role in 
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5 Future	  perspective	  
We are currently in the starting phase of revealing the function of CLEC16A and its possible 
effect on MS-disease, and still, little is known about the function of this protein. In a short-
term perspective the localization studies and endosomal studies should be completed. In a 
longer perspective, the implications for these endosomal/lysosomal defects in CLEC16A 
knocked down T cells should be functionally followed up and identification of CLEC16A 
interaction partners could be mapped to identify pathways it is involved in. This will further 
identify underlying mechanisms in MS development.  
 
5.1 Short	  term	  perspective	  
During the course of this thesis, I also made samples for Image stream analyses. A PhD 
student in the lab is now in the process of analysing these samples, and these data will 
quantify the degree of co-localization observed in the current thesis. In addition, endogenous 
staining of CLEC16A and the markers detected by overexpression (Rab4a, Rab5 and Rab7) 
should be performed to exclude that the co-localizations observed is artefacts from 
overexpressing the components analysed. For the endosomal distribution studies, the analyses 
of Image Stream data (already collected) should be guided by the conclusion from this study 
as explained in section 4.2.3. 
 
5.2 Long	  term	  perspective	  
In a longer perspective the function of CLEC16A should be further evaluated both in context 
of autophagy and receptor trafficking. In addition, the interaction partners for CLEC16A and 
pathways they are involved in should be mapped to further find the underlying mechanisms 
for T cell activation and thereby MS development.  
	  
5.2.1 T	  cell	  activation	  and	  receptor	  trafficking	  
As discussed (in section 4.2) there are several lines of evidence indicating that CLEC16A is 
involved in receptor trafficking. This should be further evaluated for TCRs in T cells, to 
investigate whether CLEC16A is involved both in receptor trafficking and T cell activation. 
As discussed, one study has shown that CLEC16A is dispensable for MHC-II presentation in 
B cells (69), but in dendritic cells, CLEC16A seems to be important for HLA-II presentation 
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to the cell surface (Marvin Luijn, personal communication). The preliminary results from our 
lab indicate that CLEC16A is not necessary for T cells to become activated and to express 
activation markers such as CD25 and CD69 when being activated through PMA and 
ionomycin (Leikfoss, Berge unpublished). However, it remains to be investigated whether 
TCR expression is CLEC16A-dependent, and further if it affects T cell activation 
downstream of the TCR, for instance by using CD3/CD28 beads. A further investigation 
regarding the role of CLEC16A in TCR recycling, and possible T cell activation in 
CLEC16A-knockdown and overexpressed T cells would be of interest to study.  
 
5.2.2 CLEC16A	  in	  autophagy	  
One cellular process involving membrane trafficking is autophagy, where defects can have 
disturbing effects on the cell. Earlier, it has been shown that when inducing autophagy in 
cells where CLEC16A is knocked out, the auotophagosomes are not being degraded (68). 
This indicates that the autophagosomes are not able to fuse with lysosomes. We observed 
increased expression of LAMP1 in CLEC16A knocked down cells (figure 3.20). A similar 
phenotype has earlier been observed in Ema-mutant cells and CLEC16A-knock-out cells. 
Ema affects the endosomal maturation between late endosome and lysosome (71), whereas 
CLEC16A affects the fusion between the autophoagosome and lysosome (68). In immune 
cells it would be interesting to further examine whether CLEC16A siRNA transfected cells 
display a defect in autophagy as has been observed for CLEC16A knockout in Min6 β cells. 
We did an attempt to examine this in T cells by staining the autophagosomes (anti-LC3) and 
lysosomes (LAMP1) to investigate whether there were any differences between controls and 
CLEC16A knocked down cells. However, the cells, in which autophagy was induced (by 
serum starvation) did not attach to the poly-L-lysine coated slides and could not be further 
analysed.  
 
5.2.3 Structural	  mapping	  of	  CLEC16A	  and	  identification	  of	  protein	  
interaction	  partners	  
To understand the role of CLEC16A-structural domains, different constructs expressing 
truncated or mutated version of CLEC16A can be generated. The phenotype can be 
investigated in transfected cells to find which structural domains are important to maintain 
the phenotype of wild-type CLEC16A and to identify the domains important for subcellular 
localization. In a longer perspective, the interaction partners of CLEC16A should further be 
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identified to better understand the pathways CLEC16A is involved in. Furthermore, it would 
be interesting to evaluate whether CLEC16A interacts with proteins encoded by other MS-
associated genes. This opens the possibility for identifying underlying mechanisms in MS 
development. 
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Appendix	  1:	  Abbrevations	  
AA - Alopecia areata 
APC - Antigen-presenting cell 
BSA - Bovine serum albumin 
CD - Cluster of differentiation 
CD - Crohn´s disease 
cDNA - Complementary DNA 
CIITA - MHC class II transactivator 
CLEC16A - C-type lectin-like domain family 16A 
CLIP - Class II-associated invariant chain peptide 
CNS - Central nervous system 
CTLD - C-type lectin-like domain 
DEXI - Dexamethasone-induced 
dH2O - Distilled water 
DNA - Deoxyribonucleic acid 
dNTP - Deoxynucleotide	  
E.Coli - Escherichia coli 
EAE - Experimental autoimmune encephalomyelitis 
ECL - Enhanced chemiluminescence 
EGFR - Epidermal growth factor receptor 
FBS - Fetal bovine serum 
FSC - Forward scatter 
GAPDH - Glyceraldehyde 3-phosphate dehydrogenase 
GFP - Green fluorescent protein 
GWAS - Genome-wide association study 
GYT - Glycerol-yeast extract-tryptone 
HC - Healthy controls 
HLA - Human leukocyte antigen 
HRP - Horseradish peroxidase 
HV - High voltage 
IFNγ - Interferon gamma 
IMSGC - International MS Genetics Consortium 
ITAM - Immunoreceptor tyrosine-based activation 
motif 
JIA - Juvenile idiopathic arthritis 
kb - Kilo bases 
kDa - Kilo Daltons 
LAMP1 - Lysosomal-associated membrane protein 1 
LB - Lysogeny broth 
Lck - Lymphocyte-specific protein tyrosine kinase 
LCL - Lymphoblastoid	  cell	  line 
MCS - Multiple cloning sites 
MHC - Major histocompatibility complex 
MIIC - MHC class II compartment 
Mq  Milli-­‐Q	  
mRNA - messenger RNA 
MS - Multiple Sclerosis 
ng  Nano gram 
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nm  Nano meter  
OD - Optical density 
PAGE - Polyacrylamide gel electrophoresis 
PAI - Primary adrenal insuffienciey 
PBC - Primary biliary cirrhosis 
PBS - Phosphate buffered saline 
PCR - Polymerase chain reaction 
PEG - Polyethylene glycol 
pfa - Paraformalaldehyd 
PIC - Protease inhibitor cocktail 
PMA - Phorbol 12-myristate 13-acetate 
PVDF - Polyvinylidene fluoride 
qPCR - quantitative PCR 
RA - Rheumatoid arthritis 
RIPA - Radioimmunoprecipitation assay buffer 
RNA - Ribonucleic acid 
RNaseP - Ribonuclease P 
RPMI - Roswell Park Memorial Institute 
RT - Room temperature 
SDS - Sodium dodecyl sulphate 
SDS-PAGE - Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
siRNA - small interfering RNA 
SNP - Single nucleotide polymorphism 
SOC - Super Optimal broth with catabolite 
Repression 
SOCS1 - Suppressor of cytokine signalling 1 
SSC - Side scatted 
SUMO - Small Ubiquitin-like Modifier 
T1D - Type I diabetes 
TAE - Tris-acetate-EDTA 
TBS - Tris-Buffered Saline 
TBS/T - Tris-Buffered Saline with Tween 20 
TCR - T cell receptor 
TE - Tris-EDTA 
TGN - Trans-golgi network 
TID - type I diabetes 
TM - Trans membrane 
TPB - TATA-box binding protein 
UV - Ultraviolet light 
WTCCC2 - Wellcome Trust Case Control Consortium 
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Appendix	  2:	  Materials	  
Material Producer  Catalog number  
 
Enzymes   	   	   	  FastAP	  Thermosensitve	  Alkaline	  Phosphatase	  	   Thermo	  Scientific	  	   EF0654	  FastDigest	  BamHI	   Thermo	  Scientific	  	   FD0054	  FastDigest	  EcoRI	   Thermo	  Scientific	  	   FD0274	  FastDigest	  NotI	   Thermo	  Scientific	  	   FD0593	  FastDigest	  SmaI	   Thermo	  Scientific	  	   FD0663	  FastDigest	  XbaI	   Thermo	  Scientific	  	   FD0684	  Klenow	  Fragment	   Thermo	  Scientific	  	   EP0054	  pfu	  Turbo	  DNA	  Polymerase	   Agilent	  Technologies	  	   600250	  PmeI	   Thermo	  Scientific	  	   ER1341	  T4	  DNA	  ligase	  	   Thermo	  Scientific	  	   EL0014	  
 
Buffers   
   20x	  PBS	   Ullevål	  substrate	  division	   	  FastAP	  Thermosensitve	  Alkaline	  Phosphatase	  Reaction	  buffer	   Thermo	  Scientific	   Supplied	  FastDigest	  reaction	  buffer	   Thermo	  Scientific	   Supplied	  Klenow	  Fragment	  reaction	  buffer	   Thermo	  Scientific	   Supplied	  pfu	  Turbo	  DNA	  Polymerase	  Reaction	  buffer	   Agilent	  Technologies	   Supplied	  T4	  DNA	  ligase	  reaction	  buffer	   Thermo	  Scientific	   Supplied	  
	  
Ladders 
 1	  kb	  plus	  DNA	  ladder	   Invitrogen	  	   10787-­‐018	  Precision	  Plus	  Protein™	  Standard	   Bio-­‐Rad	   161-­‐0374	  
	  
Components for enzymes 
 dNTP	  Mix	  100mM	   Life	  technologies	   362271	  PEG	  4000	   Thermo	  Scientific	   Supplied	  
 
Gel electrophores  
 6X	  loading	  dye	  	   Thermo	  Scientific	  	   R0611	  Ethidium	  Bromide	   MP	  Biomedical	   190202	  Seakem®	  LE	  Agarose	  	   Lonza	   50004	  TAE	  Buffer	  (50X)	   G-­‐Bioscience	   R023	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Antibiotics 
 Kanamycin	  	   Sigma	  Aldrich	   K4000-­‐5G	  Ampicillin	   Sigma	  Aldrich	   A9393	  
	  
Protein work   
   Quick	  Start™	  Bradford	  1x	  Dye	  Reagent	  	   Bio-­‐Rad	   500-­‐0105	  Quick	  Start™	  Bradford	  protein	  assay	  kit	  1	   Bio-­‐Rad	   500-­‐0201	  RIPA	   Thermo	  Scientific	   11542461	  
 
Primary antibodies 
 Anti	  TGN46	  rabbit	   AbB	  serotec	   AHP1588	  Anti-­‐CLEC16A	  polyclonal	  antibody	   Millipore	   ABN167	  Anti-­‐DDK	  monoclonal	  antibody	   Origene	  technologies	  	   TA50011-­‐100	  Anti-­‐LAMP1	  antibody	   Abcam®	   ab62562	  Anti-­‐vimentin	  antibody	   Abcam®	   EPR3776	  EGFR	  (1005)	  rabbit	  polyclonal	  IgG	   Santa	  Cruz	  biotechnology	   sc-­‐03	  GAPDH	  (6C5)	  mouse	  monoclonal	   Santa	  Cruz	  biotechnology	   SC-­‐32233	  GFP(FL)	  polyclonal	  antibody	   Santa	  Cruz	  biotechnology	  	   SC-­‐8334	  Rb	  pAb	  to	  lamin	  B1	   Abcam®	   Ab16048	  
 
HRP-conjugated secondary antibodies 
 Perioxidase-­‐conjugated	  AffiniPure	  Goat	  Anti-­‐Mouse	  IgG	   Jackson	  ImmunoResearch	   115-­‐035-­‐146	  Perioxidase-­‐conjugated	  AffiniPure	  Goat	  Anti-­‐rabbit	  IgG	   Jackson	  ImmunoResearch	   111-­‐001-­‐003	  Perioxidase-­‐conjugated	  AffiniPure	  Mouse	  Anti-­‐Goat	  IgG	   Jackson	  ImmunoResearch	   205-­‐035-­‐108	  
 
Alexa-conjugated secondary antibodies 
 Alexa	  Fluor®	  555	  F(ab)2	  Fragment	  of	  Goat	  Anti	  Mouse	  IgG	  (H+L)	   Molecular	  Probes	  ®	  by	  Life	  technologies	   A21425	  Alexa	  Fluor®	  647	  Goat	  Anti-­‐Rabbit	  IgG	   Molecular	  Probes	  ®	  by	  Life	  technologies	  	   A21245	  Alexa	  Fluor®	  647	  Rabbit	  Anti-­‐Mouse	  IgG	  (H+L)	   Molecular	  Probes	  ®	  by	  Life	  technologies	   A21239	  	  
 
Cell culture 
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 2-­‐mercaptoethanol	   Sigma	  Aldrich	   M3148-­‐100ML	  Counting	  Slides	  dual	  chamber	  for	  cell	  count	  	   Bio-­‐Rad	   145-­‐0011	  Electroporation	  Cuvettes	  4mm	  Gap	   VWR®	  	   732-­‐1137	  Fetal	  Bovine	  Serum	   HyClone®	  Thermo	  Scientific	  	   SV30160.03	  MEM	  NEAA	  (100X)	   Gibco®	  by	  Life	  technologies	   11140-­‐035	  Pen	  Strep	   Gibco®	  by	  Life	  technologies	   15140-­‐122	  RPMI	  medium	  1640	  (1X)	   Gibco®	  by	  Life	  technologies	   21875-­‐034	  RPMI	  medium	  1640	  (1X)	   Gibco®	  by	  Life	  technologies	   21875-­‐034	  Sodium	  Pyruvate	  100mM	  (100X)	   Gibco®	  by	  Life	  technologies	   11360-­‐039	  Trypan	  Blue	  solution	  0,4%	   Sigma	  Aldrich	   T8154	  
 
Immunostaining 
 Cover	  glass	  thickness	  no	  1	   VWR®	   631-­‐0146	  Hoechst	  33342	   Molecular	  Probes®	  by	  Life	  technologies	   H1299	  Polysine™	  microscope	  slides	  	   VWR®	   631-­‐0107	  Rinderalbumin	  30%	   Bio-­‐Rad	   805095	  Saponin	  from	  quilaja	  bark	   Sigma	  Aldrich	   S7900	  SlowFade®	  Gold	  antifade	  reagent	   invitrogen	   S36936	  Sodium	  Azide	  0,1M	   Sigma	  Aldrich	   08591-­‐1ML-­‐F	  
 
SDS PAGE and WB 
 10%	  Criterion™	  Tris-­‐HCl	  Gel	   Bio-­‐Rad	   345-­‐0009	  4–20%	  Criterion™	  Tris-­‐HCl	  Gel	   Bio-­‐Rad	   345-­‐0032	  7.5%	  Criterion™	  Tris-­‐HCl	  Gel	   Bio-­‐Rad	   345-­‐0005	  Extra	  thick	  blot	  paper	  filter	  paper	   Bio-­‐Rad	   1703967	  Hypercasette™	  	   Amersham	  Bioscience	  	   11642	  Hyperfilm™	  ECL	   GE	  healthcare-­‐Amersham	   28906837	  Immuno-­‐Blot	  PVDF	  membrane	   Bio-­‐Rad	   162-­‐0177	  Methanol	   Sigma	  Aldrich	   32213-­‐5L	  Restore	  Western	  Blot	  Sripping	  Buffer	   Thermo	  Scientific	   21062	  Skim	  milk	  powder	   Sigma	  Aldrich	   70166-­‐5006	  SuperSignal	  ®	  West	  pica	  Chemiluminescent	  substrate	   Thermo	  Scientific	  	   34080	  Tween®	  20	   Sigma	  Aldrich	   P1379	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Buffers for Attune Acoustic focusing cytometer 
 Attune®	  Focusing	  Fluid	   Life	  technologies	   4449790	  Attune®	  Performance	  Tracking	  Beads	   Life	  technologies	   4449754	  Attune®	  Shutdown	  Solution	   Life	  technologies	   4454955	  Attune®	  Wash	  Solution	   Life	  technologies	   A-­‐24974	  
 
Commercial kits 
 Compartmental	  Protein	  Extraction	  kit	   Millipore	   2145	  Endofree®	  Plasmid	  maxi	  kit	  (10)	   Qiagen	   12362	  QiAprep®	  spin	  miniprep	  kit	  (50)	   Qiagen	   27104	  Wizard®	  SV	  Gel	  and	  PCR	  clean-­‐up	  system	  	   Promega	   A9281	  
	  
Plasmids and siRNA 
 Dharmacon	  On-­‐target	  plus	  Non-­‐targeting	  Pool	   Dharmacon	   D-­‐001810-­‐10-­‐20	  Dharmacon	  On-­‐target	  plus	  SMART	  Pool	  CLEC16AsiRNA	   Dharmacon	   L-­‐022485-­‐02-­‐0020	  pCMV6-­‐CLEC16A-­‐MYC-­‐DDK	   Origene	   RC214696	  pEGFP-­‐C1-­‐SUMO	   Gift	  from	  Odd	  Stokke	  Gabrielsen´s	  group	   	  pEGFP-­‐N1	   Gift	  from	  Anne	  Spurkland´s	  group	   	  Rab4a-­‐mCherry	   Gift	  from	  Anne	  Spurkland´s	  group	   	  Rab5-­‐mCherry	   Gift	  from	  Anne	  Spurkland´s	  group	   	  Rab7-­‐GFP	   Gift	  from	  Anne	  Simonsen´s	  group	   	  
 
Machines and Equipment 
 Amersham	  ECL	  Semi-­‐Dry	  Blotters	  TE	  77	  PWR	   Amersham	  Bioscience	  Attune	  acoustic	  focusing	  cytometer	   Applied	  Biosystem	  by	  Life	  Technologies	  Centrifuge	  5810R	   Eppendorf	  Criterion™	  cell	   Bio-­‐Rad	  Curix	  60	   AGFA	  HealthCare	  ECM	  399	  electroporation	  system	  BTX®	   Harvard	  Apparatus	  ECM	  830	  Electro	  Square	  Porator™	  BTX	  	   Harvard	  Apparatus	  GeneGenius	  Gel	  Light	  Imaging	  System	   Syngene	  GeneGenius	  Gel	  Light	  Imaging	  System	   Syngene	  Heracell	  150i	  CO2	  incubator	  	   Thermo	  Scientific	  Innova	  4000	  Incubator	  shaker	   The New Brunswick	  MJ	  research	  PTC-­‐200	  thermal	  cycler	   GMI	  Nanodrop	  2000	  c	  spectrophometer	   Thermo	  scientific	  Nanodrop	  2000	  C	  spectrophometer	  	   Thermo	  Scientific	  
Olympus FluoView™ FV1000 BX61 confocal Olympus	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FLUOVIEW FV1000	   Olympus	  Geneious	  6.1.6	   www.geneious.com	  Illustrator®	  CC	  Tryout	   Adobe	  	  ImageJ64	   http://imagej.nih.gov/ij/	  NanoDrop	  2000	   Thermo	  Scientific	  Photoshop®	  CC	  Tryout	   Adobe	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Appendix	  3:	  Recipes	  
 
For	  Western	  blot	  analysis:	  
 
10x Tris/Glycin/SDS running buffer (5 litre):  
(0,25 M Tris, 1,92 M glycin, 1 % SDS) 
Tris base (Mm = 121,14 g/ml)  150g 
Glycin (Mm = 75.0666 g/mol)  720g 
20 % SDS (v/w)    250 ml 
dH2O      up to 5 litre 
 
Transfer buffer til 1 hr semi-dry (10 litre) 
(25 mM Tris, 192 mM glycin, 10 % methanol) 
Tris base (Mm = 121,14 g/ml)  30 g 
Glycin (Mm = 75.0666 g/mol)  144 g 
Metanol     1,0 litre 
dH2O      up to 10 litre 
 
10xTBS, ph 7.6 (5 litre) 
(100 mM Tris, 1,5 M NaCl) 
Tris base (Mm = 121,14)   60,6 g 
NaCl (Mm = 58.44)    432,8 g 
dH2O      up to approximatly 4,5 litre 
 
1 x TBS-T (3 litre) 
(10 mM Tris, 150 mM NaCl) 
10x TBS, pH 7,6    300 ml 
Tween 20     3 ml 
dH2O      2,7 litre 
 
6x Sample treatment buffer (SDS-PAGE) 
(350 mM Tris-HCl pH 6.8, 10 % SDS, 30 % glycerol, 0,175 mM Bromophenolblue) 
1,5 M Tris-HCl, pH 6.8   5,8 ml 
SDS (Mw = 288,4 g/mol)   2,5 g 
Glycerol     7,5 ml 
Bromophenolblue (Mm = 691.9 g/mol) 3 mg 





LB medium (1 litre): 
Bacto yeast extract    5g 
Bacto tryptone     10g 
NaCl      10g 
MQ-H2O      up to 1 litre 
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LB agar (1 litre): 
LB medium     1 litre 
Bacto agar     15g 
 
Gyt medium (20 ml): 
Glycerol     2 ml 
Bacto yeast extract    25 mg 
Bacto tryptone     50 mg 
MQ-H2O      up to 20 ml 
 
SOC medium (100ml): 
Bacto Tryptone    2 g 
Bacto yeast extract    0,5 g 
NaCl      0,06 g 
MgSO4*7H2O     0,25 g 
MgCl2      0,20 g 
 
10% Glycerine (100ml): 
Glycerol     10 ml 





8% PFA:  
PFA      16g 
dH2O      100 ml 
NaOH      2 ml 
10x PBS      20 ml 




PBS      2 ml 
Saponin     200 mg 
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Appendix	  4:	  Primer	  sequences	  
 
Primers for generating inserts in sub cloning: 















J-022485-22 UGUCUGAGAUGUACGCUAA 	  	  For	  subcloning	  section	  3.1.1:	  	  Primer	  combination	  1:	  EGFP_NotI_Frw	  and	  EGFPstop_Rev.	  	  Primer	  combination	  2:	  EGFP_NotI_Frw	  and	  EGFP_NotI_Rev	  
 
